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I. Abstract
Based on RNA interference (RNAi), a mechanism regulating gene expression at the post-
transcriptional  level  in  eukaryotes,  therapeutic  siRNAs are  slowly  moving towards  late
phase clinical trials. The development of therapeutic oligonucleotides is however paved
with  many challenges,  mostly  regarding  a  mean to  deliver  siRNAs in  a highly  tissue-
specific manner and to monitor their in vivo biodistribution. Two major axes are therefore
structuring this thesis, the first one being the development of a method to assess the  in
vivo biodistribution of siRNAs, and the second one aiming at unraveling the possible use of
exosomes for tissue-specific delivery.
We first  developed an assay compatible  with  various RT-qPCR assays  to  assess the
biodistribution of oligonucleotides biodistribution in mouse whole body sections. The RT-
qPCR signals are converted into an image that represents the in vivo biodistribution of the
analyzed oligonucleotide. This method, called Whole Body Scanning PCR (WBS-PCR),
has  been  first  validated  for  the  detection  of  tissue-specific  or  ectopic  mRNAs.  We
subsequently developed an assay to detect miRNAs and siRNAs by RT-qPCR, which was
validated with the WBS-PCR for the detection of tissue-specific miRNAs. An in vivo study
was then performed, aiming at determining the in vivo biodistribution of an unformulated
siRNA in mouse whole body sections. However, since more and more chemistry is being
incorporated in  therapeutic  oligonucleotides to  provide them higher  resistance towards
nucleases,  these  oligonucleotides  could  not  be  detected  anymore  by  our  assay.  We
therefore designed a novel  assay,  allowing the detection of highly chemically modified
oligonucleotides, which we called Chemical Ligation qPCR (CL-qPCR). The compatibility
of CL-qPCR with WBS-PCR was assessed by performing in vivo studies using a fully 2’-
MOE modified antagomir, an oligonucleotide targeting miR-16-5p.
Having successfully developed a method allowing the rapid determination of the  in vivo
biodistribution of therapeutic oligonucleotides, we focused in the second part of this thesis
on assessing the use of exosomes as novel oligonucleotides delivery vehicles.
Although a vast majority of siRNAs in clinical trials are delivered systemically via lipidic
nanoparticles (LNP),  some concerns have been raised with  respect  to  the difficulty  to
efficiently  design  and  generate  LNPs  displaying  tissue-specificity  and  low  toxicity.  An
increasing amount of studies reported that naturally occurring vesicles called exosomes
might be involved in inter-cellular communication via the transfer of proteins, mRNAs and
miRNAs, suggesting some degree of tissue-specific delivery potential. Moreover, the fact
that these exosomes are secreted by cells, and their presence in the circulation indicates
that these vesicles might exhibit a low lipid-induced toxicity, made them ideal transporters
candidates  of  therapeutic  oligonucleotides.  We  first  investigated  ways  to  efficiently
characterize  exosomes  isolated  from  cell  culture  supernatant.  An  extensive
characterization of exosomes was crucial because of the subsequent  in vivo injections,
planned to demonstrate the utility of exosomes as oligonucleotides delivery vehicles. We
therefore selected a series of criteria which for us accounted for the presence of exosomes
in a sample. These criteria are based on exosomes hallmarks such as particle size, the
detection of exosomes-enriched miRNAs, as well as the detection of exosomal proteins.
We then focused on the identification of an efficient exosomes isolation method from cell
culture supernatant. We therefore compared various methods described in the literature
for exosomes isolation, such as the commonly used differential ultracentrifugation, or the
recently commercialized ExoQuick kit. We also tested isolation methods based on either
particle size segregation, or taking advantage of the virus-like characteristics of exosomes.
None of the samples prepared by using these methods did meet all criterions which could
have  confirmed  the  presence  of  exosomes  in  the  purified  cell  culture  supernatants.
However, further characterization of one of the exosomes isolation methods confirmed that
cells  might  not  only  secrete  miRNAs encapsulated in  exosomes,  but  also  miRNAs in
complex with a member of the RISC complex, namely Ago2.
Although  CL-qPCR,  in  combination  with  WBS-PCR,  would  allow  the  detection  and
biodistribution of  many kinds of  unmodified,  or  heavily chemically  modified therapeutic
siRNAs, we were unable to demonstrate the use of exosomes as siRNA delivery vehicles.
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2'-MOE 2'-O-Methyl-etoxyethyl
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AD Alzheimer's disease
ag Attogram
Ago2 Argonaute protein 2
Alix/PDCD6IP Programmed cell death 6 interacting protein
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fg Femtogram
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Lamp2b Lysosome associated Protein 2b
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LNA Locked Nucleic Acid
LNP Lipidic Nanoparticle
log Logarithm
max Maximum
MBP Myelin Basic Protein
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Min Minute
miRNA MicroRNA
mL Milliliter
MODC Monocyte derived Dendritic Cell
mRNA Messenger RNA
Mrp4 Multidrug resistance protein 4
MS Mass Spectrometry
MVB Multivesicular Body
Myh6 Myosin Heavy chain 6
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n.s. Non-significant
ng Nanogram
nm Nanometer
NTC No Template Control
PBS Phosphate Buffer Saline
PC Pachyonichia congenita
PCR Polymerase Chain Reaction
PEI Polyethylenimine
pg Picogram
PO-MOE PO backbone MOE modified AMO
PS Phosphorothioate
PSP Progressive Supranuclear Palsy
PTGS Post-Transcriptional Gene Silencing
qPCR Quantitative Polymerase Chain Reaction
QWBA Quantitative Whole Body Autoradiography
RISC RNA-induced silencing complex
RNA Ribonucleic Acid
RNAi RNA interference
rRNA Ribosomal RNA
RT Reverse Transcription
RT-qPCR
Reverse Transcriptase-quantitative Polymerase Chain 
Reaction
RVG Rabies Virus Glycoprotein
sem Standard error of the mean
shRNA Small hairpin RNA
siRNA Small interfering RNA
SSB Sjögren's syndrom b
STDEV Standard deviation
TCEP Tris(2-carboxyethyl)phosphine
TEM Transmission Electronic Microscopy
TFF Tangential Flow Filtration
TRS Target Recognition Sequence
µm Micrometer
V Volt
WBS Whole Body Section
WBS-PCR Whole Body Scanning PCR
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III. Introduction
In an attempt to propose an increasing choice of therapeutic possibilities to cure various
diseases, or to at least ease the life of chronically ill patients, pharmaceutical companies
invest  many  efforts  in  the  development  of  innovative  therapeutic  means.  After  the
extensive and successful use of small molecule compounds, as well as the development
of therapeutic antibodies, pharmaceutical companies started assessing the use of a novel
class of therapeutic molecules, namely therapeutic oligonucleotides.
A. Development of antisense therapeutic oligonucleotides
Since the first  mention of  the possibility  to  use oligonucleotides as therapeutic  agents
against viruses in 1978 (1,2), oligonucleotides have been attributed the potential to drug
targets considered as “undruggable” by small molecules (3). Although biological activity,
intracellular uptake and especially delivery of these oligonucleotides are still major hurdles
in the therapeutic oligonucleotides field,  many efforts have been invested to overcome
these challenges (4). The main interest in using oligonucleotides as therapeutic molecules
is  their  ability to  hybridize to  cellular nucleic acids,  being DNA or RNA and to induce
nucleic  acid  degradation,  transcriptional  or  translational  arrests.  The  first  class  of
therapeutic oligonucleotides, called antisense oligonucleotides, were single-stranded DNA
molecules which were tested for their potential use in early attempts at slowing down the
proliferation of HIV viruses in vitro by hybridizing to complementary sites on viral mRNAs
(5). The development of techniques allowing an automated high-throughput production of
oligonucleotides, such as the MerMade automated synthesizers, raised much hope for the
therapeutic  applicability  of  these  antisense  oligonucleotides  (6).  The  development  of
antisense oligonucleotides resulted in early 2013 in the approval by the American Food
and Drug Administration (FDA) of Kynamro™, an antisense oligonucleotide produced by
Isis Therapeutics (7), for the intravenous treatment of inherited hypercholesterolemia. This
clearly confirms the potential  held by oligonucleotides based drugs, although antisense
oligonucleotides are  not  the  only  class  of  potentially  therapeutic  oligonucleotides.  The
evidence of a silencing mechanism based on double stranded RNAs in plants (8) led to the
unraveling of the RNA interference (RNAi) mechanism, also called Post-Transcriptional
Gene Silencing (PTGS), as well  as to the identification of a population of endogenous
regulatory RNAs, called micro RNAs (miRNAs).
B. MicroRNAs, key elements of the Post-Transcriptional Gene 
Silencing
MicroRNAs (miRNAs) are a class of endogenously expressed 20 to 25 nucleotides long
double-stranded RNA molecules implied in the regulation of protein expression (9). The
mechanism by which miRNAs have the capability to regulate gene expression is known as
Post-Transcriptional  Gene  Silencing  (PTGS)  (10)  (Fig.  1A).  The  production  of  active
miRNAs occurs via the maturation of precursor double-stranded RNA molecules called pri-
miRNAs  (11).  The  pri-miRNAs  are  processed  by  the  Microprocessor  protein  complex
composed  of  Drosha  and  DGCR8 into  a  pre-miRNA intermediate.  The  pre-miRNA is
guided to nuclear pores by the Exportin 5 protein and is subsequently exported to the
cytoplasm where it undergoes cleavage in active miRNAs by the Dicer protein. The active
strand of the miRNA is then loaded in the RNA-Induced Silencing Complex (RISC), and
more specifically in the Argonaute 2 protein (Ago2). The single-stranded miRNA loaded in
this activated RISC is now able to fully or only partially bind to complementary sequences
on its target messenger RNA(s) (mRNA), inducing mRNA degradation and thus reducing
the production rate of the protein encoded by this mRNA.
Figure 1: Post-Transcriptional Gene Silencing (PTGS) mediated by miRNA (A), shRNA (B) and siRNA (C)
Because of the central  role that PTGS plays in protein expression, the deregulation of
miRNAs expression can be the trigger for many diseases, such as cancer for example (12-
14). This predominant role in the control of protein expression offers on the other hand
perspectives for the development of new therapeutic compounds (15). It would indeed be
possible, by using miRNAs mimics to act upstream of the production of a protein, instead
of  using  a  small  molecule  compound  targeting  a  protein.  Such  a  strategy  could  be
beneficial in many disease onsets where a single or a subset of disease-related protein is
produced, as in cancers, viral infection, or inherited genetic diseases for example. It has
therefore been investigated whether oligonucleotides could be used as therapeutic agents.
C. Therapeutic action of siRNAs
The first observation of RNAi-induced silencing in animal cells using short small interfering
RNA molecules (siRNAs) (16) together with the publication of studies showing the higher
potency of siRNA molecules over antisense oligonucleotides (17), was a trigger for the
development of therapeutic siRNAs.
12
siRNAs, as other regulatory RNAs such as miRNAs, are loaded into the RISC complex
with  the potential  of  triggering post-translational  silencing (18) and therefore inhibit  the
production of a target protein by either degrading its coding mRNA or by translational
repression. siRNAs can be found in two flavors, either genomically expressed as small
hairpin RNAs (shRNAs) (Fig. 1B) or present in the cytoplasm as functional siRNAs after
systemic delivery for example (Fig. 1C). Although these strategies sound very appealing, it
has to be noted that the non-controlled integration of shRNAs or siRNAs in cells can lead
to a saturation of the miRNA machinery by shRNAs and siRNAs, a phenomenon already
known for having caused mice death (19).  The development of  siRNAs as therapeutic
compounds has to overcome still a few technical and biological hurdles before being able
to make them commercially available  (20,21),  the most  important  being tissue-specific
delivery of  siRNAs (22,23).  Despite the many challenges faced by the siRNA, several
siRNA candidates have already entered clinical studies (20,24-27) (Table 1).
Indication Compound name Company Clinical Phase
Age related Macular Degeneration AGN211745 Merck/Allergan II
 PF-4253655 Silence Therapeutics/Pfizer/Quark II
Anti-viral ALN-RSV Alnylam II/III
Miravirsen Santaris II
ARC-520 Arrowhead Research I
 TKM-Ebola Tekmira I
Diabetic Macular Oedema PF-04523655 Silence Therapeutics/Pfizer/Quark II
Hypercholesterolemia ALN-PCS Alnylam I/II
TKM-ApoB Tekmira I/II
 SPC4955 Santaris I
Non-arteritic Anterior Ischemic Optic 
Neuropathy QPI-1007
Quark 
Pharmaceuticals/BioSpring I
Ocular pain SYL1001 Sylentis II
Oncology FANG Gradalis II
ALN-VSP Alnylam I/II
Atu027 Silence Therapeutics I/II
CEQ508 Marina Biotech I/II
CALAA-01 Arrowhead Research I
EZN-2968 Santaris I
NCT00672542 Duke University I
siG12D LODER Silenseed I
 TKM-PLK1 Tekmira I
Open Angle Glaucoma SYL040012 Sylentis II
Pachyonychia Congenita TD101 Pachyonychia Congenita Project/TransDerm I
Prevention of Delayed Graft Function QPI-1002 Silence Therapeutics/Novartis/Quark II
TTRmediated amyloidosis ALN-TTR02 Alnylam II
 ALN-TTRsc Alnylam I
Table 1: siRNA candidates in clinical trials
As can be seen from the different therapeutic areas targeted by the siRNAs presented in
Table 1, a major part of the siRNA candidates aim at curing diseases such as inherited
genetic diseases (28), or cancer (27). The tissue-specific delivery of these oligonucleotides
is a major hurdle in the development of this technology, but over the years, many solutions
have been tested to overcome this challenge (29).
D. Delivery strategies for siRNAs
Although siRNA delivery based on lipidic nanoparticles seems to be the most frequently
used delivery method for siRNAs (30-32), a variety of other delivery routes has also been
investigated.  These delivery  methods  include local  injection  of  siRNAs,  conjugation  of
siRNAs to targeting-peptides,  as well  as virus-mediated delivery,  and encapsulation of
siRNAs in exosomes.
D.1. Lipidic Nanoparticles (LNP) mediated delivery of siRNAs
Most  of  the  clinical  siRNA candidates  are  administered  via  small  lipidic  nanoparticles
(LNP), which are known to allow delivery of siRNAs in tissues (33). LNPs are composed of
a mixture of positive and neutral lipids and are able to form complexes with the negatively
charged siRNAs. Care has however to be taken as to how these LNPs are formed, since
LNPs displaying too many positive charges may elicit severe dose-dependent toxic effects
(34).  However,  a  thorough  and  careful  design  of  the  LNPs  used  for  siRNA delivery,
allowed  to  generate  formulations  not  eliciting  severe  toxicities,  such  as  the  ALN-VSP
siRNA from Alnylam (35,36). The lipid composition of the LNPs can also impact the siRNA
delivery efficiency to a given tissue, as could already be observed for liver-targeting LNPs
(37,38).
D.2. Local injections of siRNAs
An alternative delivery route for siRNA consists in injecting an unformulated siRNA directly
in the tissues where its action is required. This strategy has been successfully used in a
Phase  Ib  trial  of  the  TD101  siRNA,  aiming  at  alleviate  the  symptoms  of  a  rare  skin
disorder, pachyonichia congenita (PC) (39). This siRNA has been designed to selectively
target  the  N171K  mutant  of  the  keratin  6a  mRNA,  responsible  for  the  inherited  PC
disorder. The scientists who developed this compound adopted a strategy well suited to
increase the selectivity of their compound, namely to directly inject siRNA subcutaneously
in the callus, an area of thickened skin and accumulation of keratin, characteristic of this
disease. The rationale of this strategy is to circumvent the difficulties caused by systemic
delivery by injecting the siRNA only where its action is required. Furthermore, in the case
of a systemic escape of the siRNA, the absence of any chemical modifications makes it
highly  sensitive  to  degradation by nucleases in  the circulation (40).  One pitfall  of  this
delivery  method  is  however  the  necessity  to  perform  frequent  injections,  which  can
furthermore be extremely painful for the patients. Solutions to this problem can however be
found, such as applying the siRNA in a nanopatch, an apparently painless way of injection
(41).
The global applicability of such a strategy is therefore restricted to only a few diseases
where subcutaneous injection might be employed.
D.3. siRNAs conjugated to cell-penetrating peptides
Another  way  of  delivering  siRNAs to  specific  sites  resides  in  their  coupling  to  or  co-
injection with cell penetrating peptides. For the treatment of Hepatitis B virus infection, it
was  reported that  HBV-siRNAs,  when coinjected with  an  hepatocyte-targeting peptide,
could successfully reduce the amount of HBV mRNA specifically in hepatocytes (42). The
use  of  such  peptides  has  the  advantage  of  being  fully  biodegradable,  lowering  any
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adverse  effects  that  could  occur  because  of  systemic  administration.  However,  these
peptides present the disadvantage of potentially raising immune responses (43). Another
disadvantage of using this kind of delivery vehicle is that the siRNA is fully exposed to the
plasma nucleases, requiring to chemically modify the injected siRNA to confer elevated
resistance towards nucleases (40).
The possibility to design small peptides binding specifically to a tissue-specific receptor,
allowing  a  tissue-specific  uptake  into  only  a  limited  amount  of  cells,  offers  many
possibilities that can be applied to other delivery routes.
D.4. Virus particles-based delivery of siRNAs and shRNAs
The use of virus particles in RNAi therapeutics has also been evaluated, and the use of
adenoviral vector have been shown to be quite successful, at least in vitro, in inhibiting the
replication of dengue virus in cells (44). The use of viral vectors was motivated by the
possibility  to  insert  coding  sequences  with  a  size  up  to  1.9  kb  in  the  virus  genome,
enabling the use of small-hairpin RNAs (shRNA) (45). These shRNAs are 50 to 60 bases-
long oligonucleotides which are able to form double stranded stem-loop structures after
having been transcribed. Since these molecules are similar to pre-miRNAs, they can be
processed into active siRNAs by the action of Dicer (46), and are therefore able to trigger
RISC-driven  knock-down.  The  potential  pitfall  of  this  delivery  method  is  however  the
possibility  for  the  patients  to  elicit  strong  immune response,  since  the  majority  of  the
human population is able to recognize adenoviral antigens (47).
D.5. Exosomes as siRNA delivery vehicles
Ways  to  circumvent  this  hurdle  could  be  found  in  the  use  of  naturally  occurring
microvesicles secreted by most cells, called exosomes, in combination with tissue-specific
viral targeting peptides (48). These vehicles are 80 to 100 nm large lipidic vesicles and are
known to be involved in intercellular miRNA trafficking (49,50), designating them as ideal
candidates for siRNA transport. Displaying a tissue-targeting viral  peptide on exosomal
transmembrane proteins might be a way of selecting the tropism of these vehicles and to
purposely  direct  exosomes  towards  a  given  tissue  or  subset  of  cells  presenting  the
adequate receptor. A mouse in vivo study based on this principle has been performed in
the Wood group, and was based on the use of a rabies viral glycoprotein (RVG) fused to
the exosomal Lysosome associated membrane protein 2b (Lamp2b), in order to direct the
exosomes to the brain via systemic delivery (51).  According to  this study,  it  would be
possible to use engineered exosomal vehicles for tissue-specific delivery of siRNAs and to
observe gene silencing specifically in the brain. In a broader context, however, the use of
such a delivery route could be used to deliver oligonucleotides in a highly specific tissue-
specific manner.
IV. Development of Whole-Body Scanning PCR (WBS-PCR), a highly 
sensitive method to study the biodistribution of mRNAs, noncoding 
RNAs and therapeutic oligonucleotides
A. Introduction
The successful development of therapeutic oligonucleotides relies on major advances on
the delivery, format, and analytical fronts. As discussed previously, several options have
been evaluated for the in vivo delivery of therapeutic oligonucleotides. However, not only
should  delivery  means  be  developed  for  the  successful  application  of  therapeutic
oligonucleotides,  but  also  reliable  analytical  methods  for  their  quantification.  Over  the
years, many techniques have been developed and optimized to provide highly sensitive
and specific detection of siRNAs in biological samples. Since siRNAs are morphologically
very close to miRNAs, it  is quite logically that methods based on northern blot, in situ
hybridization but also qPCR were assessed first for the quantification of siRNAs (52,53).
The use of northern blot for the quantification of siRNAs might however be largely limited
by  its  throughput  and  the  fact  that  this  method  is  rather  time-consuming.  In  situ
Hybridization (ISH) offers the interesting feature of showing high resolution biodistribution
data, almost down to subcellular level. Unfortunately, this method is very time-consuming
as well, and a given sample can only undergo one round of In situ Hybridization analysis.
Many efforts were also invested in using mass spectrometry in order to quantify siRNAs
(54,55), however this method still suffers from serious sensitivity problems (56). Compared
to these methods, RT-qPCR appears to be one of the best methods for the quantification
of siRNAs, mainly on account of its high specificity and sensitivity (57). However, classical
sample preparation methods for  in vivo tracking of siRNAs require long handling times,
both  for  organs  sampling,  but  also  for  RNA  extraction  and  purification.  There  were
therefore  efforts  made in  order  to  track siRNAs  in  vivo by using  fluorescently  labeled
siRNAs (58).  However,  fluorescent  labeling  of  the  oligonucleotides  to  perform  in  vivo
biodistribution  studies  may  alter  its  physic-chemical  properties  with  the  danger  of
modifying its biodistribution properties as well  as biological  efficacy (59).  We therefore
oriented ourselves towards methods able to detect oligonucleotides in their native form
such as RT-qPCR not only on RNA extracted from sampled organs, but in whole body
sections,  such  as  the  ones  generated  for  Quantitative  Whole  Body  Autoradiography
(QWBA) (60). Such a method would indeed allow to fairly quickly establish the  in vivo
biodistribution  pattern  of  a  therapeutic  oligonucleotide  combined  to  various  delivery
vehicles and to therefore allow a direct comparison of different delivery methods. This is
why we developed a method called Whole-Body Scanning PCR (WBS-PCR) allowing the
quantification of various RNA and DNA based molecules by qPCR-based techniques (61).
To achieve this, we first had to demonstrate whether it was possible to generate  in vivo
biodistribution patterns of known tissue-specific mRNAs. This is indeed a crucial step to
evaluate the highest resolution achievable by this method and to confirm its specificity. We
subsequently  had  to  develop  a  RT-qPCR  method  capable  of  detecting  short
oligonucleotides such as miRNAs and siRNAs, with high specificity and high sensitivity.
An additional challenge resides in the increasing amount of chemical modifications such
as 2’-fluoro, 2’-O-methyl, 2’-O-methyl-etoxyethyl (2’-MOE) (Fig. 2) that are developed and
incorporated  in  therapeutic  oligonucleotides  (62)  to  increase  their  pharmacokinetic
properties as well as their resistance towards nucleases (40,63). These modifications have
the disadvantage of making oligonucleotides incompatible with enzyme-based detection
methods, such as PCR for example (61). Consequently, we aimed at developing a qPCR-
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based method for the detection of heavily chemically modified oligonucleotides such as
antagomirs,  small  oligonucleotide  capable  of  binding  specifically  to  a  miRNA  and  to
sequester it away from its biological targets.
Figure 2: Chemical modifications applied to oligonucleotides and nucleotides analog used for research or therapeutic
applications
In  this  chapter,  we  will  discuss  the  development  of  the  Whole  Body  Scanning  PCR
method, and investigate the applicability of this method for the detection of various coding,
noncoding, and heavily chemically modified oligonucleotides.
B. Validation of the Whole Body Scanning PCR on messenger RNAs
The  efficient  purification  of  various  nucleic  acids  such  as  mRNAs,  miRNAs,  siRNAs,
antagomirs,  but  also  genomic  DNA  can  be  quite  challenging  because  of  the  physic-
chemical properties of these molecules. Many kits are commercially available to efficiently
purify a specific subset of nucleic acids, taking advantage of their properties such as size
or hydrophilicity. In the case of Whole Body Scanning PCR however, we had the need for
an extraction method allowing efficient extraction of all these different nucleic acids, from
short miRNAs to genomic DNA. This is a crucial feature especially in the case of sagittal
whole body sections (Fig. 3), since not only must the lysis buffer be able to isolate any
nucleic acid material, but it also has to be able to extract material evenly across various
tissues. We therefore investigated the possibility to use a lysis buffer without the need of
any  additional  purification  step  which  could  have  led  to  a  bias  in  the  nucleic  acid
population  extracted  from  cells.  Various  methods  have  been  developed  for  RNA
extraction, however the RNA population obtained can vary depending on the method used,
some favoring miRNAs, whereas other favor large RNAs (64).
 Figure 3: Whole body section typically used in QWBA and Whole Body Scanning PCR experiments
The first advantage of such a method is to allow a very quick sample preparation since
once  the  tissues  are  lysed,  they  do  not  require  to  undergo  additional  extraction  or
purification steps, and an additional advantage of such an approach is the capability to
detect genomic signals allowing “per-cell” signal normalization since there are only two
genomic copies of each gene per cell (see section IV.B.2.b). We can therefore establish a
direct link between genomic signals and cell count, thus enabling to correct for the different
extraction efficiencies and cell density variations encountered on a whole mouse cross-
section (65). It therefore also enables to compare relative expression signals of an RNA
target between different mouse sections. These lysis buffers, on the other hand, might
interfere with enzymatic reactions on account of their high salt concentrations and of the
protein denaturants and chelating agents they contain. The sensitivity offered by RT-qPCR
can nevertheless be used to overcome this disadvantage, since a single dilution step may
be sufficient to dilute out the inhibitory components of the lysis buffers. In order to identify
the lysis best suited to our needs, we quantified the same RNA target in samples prepared
using three different lysis buffers and comparing the signal intensities obtained, as well as
the dilution factor that had to be applied to the lysates to allow compatibility with RT-qPCR.
From the various lysis buffers tested, the OTX Lysis Buffer supplemented with TCEP, a
buffer originally designed for the extraction of oligonucleotides from biological samples for
LC-MS analysis, was in our hands the most compatible with RT-qPCR. The reason why
this buffer was supplemented with  TCEP was because of its ability to reduce disulfide
bonds, therefore inactivating the nucleases present in the samples, an important feature
for the samples conservation. Since this compound is able to inhibit nucleases, it is also
capable of inhibiting the enzymes required for RT-qPCR amplification, hence the need to
first  validate the use of  this buffer  on mouse tissues prior to  testing it  on whole body
sections.
B.1. Validation of the sample preparation procedure on tissues
To assess the efficiency of our sample preparation method, we subjected various tissues
to total  RNA extraction using the classical Trizol method and prepared as well  tissues
lysates using the OTX Lysis Buffer supplemented with TCEP. A small panel of tissues was
selected, including soft tissues such as brain and liver, but also more fibrous tissues like
heart and skeletal muscles.
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Figure 4: Detection of tissue-specific mRNAs in total RNA purified with Trizol (a) and in tissue lysates prepared with
OTX Lysis Buffer (b). The expression of Insulin-Like Growth Factor Binding Protein 1 (IGFBP1), Myosin Heavy Chain 6
(Myh6) and Myelin Basic Protein (Mbp) was investigated in Thymus (Th), Lung (Lu), Heart (H), Skeletal Muscle (S.M.),
Kidney (K), Brain (B), Liver (Li), Spleen (S) and Spinal cord (S.c.)
We compared both sample preparation methods by investigating the relative expression
signals obtained for three well-characterized tissue-enriched mRNAs, namely Insulin-Like
Growth Factor Binding Protein 1 (IGFBP1),  Myosin Heavy Chain 6 (Myh6) and Myelin
Basic  Protein  (Mbp).  All  signals  are  shown  as  %  relative  expressions  where  100%
corresponds to the highest  signal  detected for  each gene.  Relative expression signals
obtained  from  RNA  samples  were  normalized  against  18S  rRNA,  whereas  signals
obtained in  tissue lysates  were  normalized against  genomic  18S.  Although data  were
normalized using different methods, both the RNA samples (Fig. 4a) and tissue lysates
(Fig. 4b) displayed similar results confirming the expression of IGFBP1 in liver and kidney
(66), the heart-specific expression of Myh6 (67) and the detection of Mbp in the brain (68).
Surprisingly, we could observe a small difference in IGFBP1 levels in liver. Although the
IGFBP1 relative  expression  in  liver  total  RNA is  highly  similar  to  the  IGFBP1 relative
expression  obtained  in  kidney,  there  is  a  non-negligible  difference  in  IGFBP1  levels
between kidney and liver tissue lysates. This difference can be due to the fact that the
samples  used  for  RT-qPCRs  performed on  total  RNAs  are  all  set  to  the  same  RNA
concentration and normalized using 18S rRNA relative expression, whereas in the case of
tissue  lysates,  the  data  only  undergoes  the  normalization  using  18S  rRNA  relative
expression.
Taken  together,  this  result  confirmed  the  possibility  to  detect  endogenous  mRNAs  in
samples prepared with OTX Lysis Buffer.
B.2. Detection of messenger RNAs in mouse whole body sections
The concept of the whole-body-scanning PCR is to be able, in one single PCR run, to
establish the  in vivo biodistribution pattern of a target RNA molecule, or any therapeutic
oligonucleotide  available.  Such  a  concept  was  already  established  to  monitor  the
biodistribution of radioactively labeled compounds in a method called Quantitative Whole-
Body Autoradiography (23). However in the case of WBS-PCR, it would be possible to
monitor the biodistribution of any oligonucleotide detectable by PCR-based techniques.
Briefly, the whole-body-scanning PCR makes use of 40 μm mouse sagittal cross-sections,
typically used in QWBA studies, overlaid on a 1536-well plate filled with OTX Lysis Buffer
supplemented with TCEP, since it was previously demonstrated that OTX Lysis buffer was
suited for the analysis  of  mRNAs biodistribution patterns.  The plate was subsequently
sealed and inverted a few times, allowing a very local lysis. The plate was then centrifuged
in order to collect the lysates at the bottom of the plate. Transfer of the lysates to a 384-
well plate and their dilution in RNase-free water made the lysates ready for downstream
PCR analyses. The resolution offered by WBS-PCR is therefore dictated by the size of the
lysis  plate,  which  is  in our case a 1536-well  plate.  In  order to  determine whether  this
resolution is sufficient to observe tissue-specific expression patterns, we performed WBS-
PCRs  showing  the  biodistribution  of  the  same  set  of  tissue-specific  mRNAs  tested
previously on tissue lysates and total RNA.
B.2.a) Conversion of qPCR signals to overlaid heat maps
Figure 5: Comparison of two visualization strategies for WBS-PCR results. Relative expression data obtained using
WBS-PCR were depicted using either a 3-D bar graph representation (a) or using the TissueView™ imaging software (b)
Visualization  of  the  results  obtained  by  WBS-PCR  was  an  important  step  in  the
development of the WBS-PCR method. It  was crucial to identify a visualization method
allowing to clearly visualize the biodistribution of an oligonucleotide in a mouse section.
We therefore  tested two  imaging methods  using  the  relative  expression  of  Myh6  and
genomic 18S. The first method makes use of a 3-D bar graph overlaid on a picture of the
analyzed mouse section (Fig. 5a). In the case of a localized expression pattern such as
the one obtained for the heart-specific Myh6 (Fig. 5a, upper panel) the 3-D bar graph
representation allows a clear visualization of the relative expression data. However, for a
broader expression pattern, such as the one obtained for genomic 18S for example (Fig.
5a, lower panel) the 3-D bar graph representation makes it  difficult  to appreciate and
thoroughly analyze the obtained data. We therefore tested a second method using an MS-
data  imaging  software  known  as  TissueView™  (69,70)  to  display  relative  expression
signals obtained by WBS-PCR (Fig. 4b). In order to generate these images, data analyzed
in a spreadsheet software was converted into a heat map, in a format compatible with the
TissueView™ software.  This  heat  map was  subsequently  overlaid  on  a picture  of  the
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analyzed mouse section using the coregistration function of the imaging software allowing
a precise alignment of the heat map on the section picture. The resulting images show a
much clearer expression pattern, especially because of the conversion of the data into
heat maps. It is indeed difficult to appreciate variations in signal intensity on a 3-D bar
graph  since  high  values  in  a  3-D  bar  graph  can  hide  lower  data  points.  The  Myh6
expression pattern shows in the case of an image generated by TissueView™ a strong
colocalization  with  the  heart  region  (Fig.  5b,  upper  panel)  which  could  not  be  fully
appreciated on the 3-D bar graph depiction. For the same reasons it  is also easier to
appreciate the variations of signal intensity in the uniform biodistribution pattern obtained
for genomic 18S (Fig. 5b, middle panel).
We therefore decided to depict  every biodistribution pattern obtained by WBS-PCR by
using the TissueView™ software.
B.2.b) Genomic 18S versus 18S ribosomal RNA correction
Since a mouse whole body section displays different cell densities and tissue organization
between various organs, we had to identify a normalization method able to account for
these variations across the section. A common method used to normalize RT-qPCR data
is by using 18S rRNA as a normalizer, since the 18S rRNA levels reflect the RNA amounts
present in a sample (71). Although this method is widely accepted among the scientific
community, some authors contest the validity of using 18S rRNA alone as a normalizer,
since the level of ribosomal RNA may vary between various tissues (72). It is therefore
recommended to use a dozen housekeeping genes for accurate normalization (73,74).
The quantification  of  a  dozen of  housekeeping genes would  be impractical  since that
would interfere with the desired utility of the WBS-PCR to provide quickly biodistribution
data. We therefore adopted another method for RT-qPCR normalization. Interestingly, it
was also reported that normalization using genomic sequences can be used to absolutely
quantify  transcripts,  and  in  our  case  therapeutic  oligonucleotides  as  well  (75).  We
therefore conducted a study comparing two normalization methods, one based on 18S
rRNA and one making use of the 18S genomic DNA copies available in the lysates (Fig.
6).
We quantified two target RNAs by WBS-PCR, namely Myh6 and miR-16-5p (see section
IV.C.1.a), and normalized the obtained expression data using either 18S rRNA or genomic
18S. The expression patterns obtained for both 18S rRNA and genomic 18S show a broad
coverage of the mouse section (Fig. 6a). Interestingly, areas such as brain, olfactory bulb,
spinal cord and liver showing high amounts of 18S rRNA display high levels of genomic
18S as well. This can be explained by the fact that tissues with high cell density display
high DNA and RNA levels. Despite these similarities, the 18S rRNA data seems to be not
as uniform across the section as the 18S genomic data, since the region corresponding to
the gastro-intestinal tract show surprisingly low signals compared to surrounding areas. In
order to identify the best normalizer, we measured miR-16-5p (Fig. 6b) and Myh6 (Fig. 6c)
levels  in the section. The miR-16-5p biodistribution pattern was highly affected by the
normalizer used. Indeed, the uncorrected miR-16-5p data (Fig. 6b, upper panel) shows
high miR-16-5p amounts in the brain, heart, spinal cord, and blood vessel. The 18S rRNA
corrected data on the contrary, showed no miR-16-5p in the brain, and overall low signals
across the section. Moreover, a high signal peak could be observed in the gastro-intestinal
tract, therefore leading to a completely distorted biodistribution pattern compared to the
non-normalized data (Fig. 6b, middle panel). This distortion is mainly due to the fact that
the  18S  rRNA  expression  levels  show  high  variations  across  the  section,  therefore
exacerbating the signal variations during normalization. The genomic 18S corrected data
on the other hand, showed a uniform expression pattern across the section with slightly
elevated levels in the brain, spinal cord, heart and gastro-intestinal tract (Fig. 6b, lower
panel). This corrected dataset reflects best the miR-16-5p biodistribution pattern than the
18S rRNA biodistribution pattern. The normalizer used to correct the Myh6 mRNA data, on
the other hand, did not result in similar data distortions as could be observed for the miR-
16-5p data.  The highly  heart-localized expression  data  showed indeed similar  results,
independent of the normalizer used (Fig. 6c).
Figure 6: Impact of the normalization method on biodistribution data. Biodistribution pattern of genomic and RNA 18S
(a) used for the normalization of miR-16-5p (b) or Myh6 (c) expression data
This study shows that the choice of the normalizer is crucial for efficient data correction.
However, it could also be observed that genes showing a broad expression pattern are
more prone to  distortions compared to  genes displaying  a highly  localized expression
pattern  when using a  non-optimal  normalizer  such as  18S rRNA for  example.  This  is
especially important for the biodistribution pattern of a therapeutic oligonucleotide, which
might  not  display  a  uniform biodistribution.  In  such  cases,  a  non-uniformly  expressed
normalizer  can  distort  the  biodistribution,  such  as  showing  “artificially”  highly  elevated
signals in regions where the normalizer is only dimly expressed. We therefore decided to
use genomic 18S as a normalizer in the rest of these studies.
B.2.c) Detection of endogenous tissue-specific mRNAs
The first step of the validation of the WBS-PCR method consisted in confirming the tissue-
specific  expression  pattern  of  tissue-specific  mRNAs  previously  tested  on  a  panel  of
tissues.
Genomic 18S relative expression was measured and was used to assess the extraction
efficiency of  the lysis  of  the section  (Fig.  7a,  lower panel).  An overall  homogeneous
biodistribution pattern was observed across the section with elevated genomic 18S levels
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in brain and along the spinal cord. These higher signals could either indicate regions with
higher cell densities, or regions displaying better extraction efficiencies. In order to take
these variations in account during gene expression analysis, relative expression signals
obtained  for  each  mRNA  were  normalized  against  genomic  18S  signals.  mRNAs
biodistribution patterns (Fig. 7a, upper panels), in contrast to genomic 18S signals, did
not  result  in  a  homogenous  expression  across  the  section,  but  to  tissue-specific
expression patterns corroborating the expression patterns obtained in tissue lysates (Fig.
4b). We could indeed observe that IGFBP1 mRNA expression pattern co-localized with
liver, while the Myh6 mRNA signals co-localized with the region of the heart. Unfortunately,
there were no kidney tissues on this section, that is why we could detect IGFBP1 only in
liver. Interestingly we could detect Mbp mRNA not only in brain, but also in regions along
the spinal cord, as could already be seen on total RNA purified from tissues (Fig. 7b).
Figure 7: Biodistribution of tissue-specific endogenous coding mRNAs determined by WBS-PCR. (a) Relative
expression data obtained by WBS-PCR for IGFBP1, Myh6, and Mbp mRNAs. Major organs and tissues were indicated
such as brain (B), spinal cord (Sc), salivary gland (Sg), heart (H), liver (Li), blood vessel (Bd) and gastro-intestinal tract
(GI). (b) Relative expression of the MBP mRNA in total RNA purified from tissues. Values are averages of quadruplicate
measurements. Error bars, STDEV (n=4)
Taken together, these data suggest that the sample preparation based on the use of OTX
Lysis  buffer  supplemented with  TCEP is  compatible  with  WBS-PCR.  Furthermore,  the
resolution offered by the 1536-well lysis plate was sufficient to visualize the biodistribution
pattern of a small panel of tissue-specific mRNAs.
B.2.d) Detection of ectopic human mRNAs
In order to further characterize the resolution level that can be achieved using WSB-PCR
for the biodistribution of RNAs, we visualized the human-specific mRNAs expressed by a
human colorectal carcinoma HCT-116 tumor grown subcutaneously in a mouse model. We
therefore  performed  WBS-PCR  against  human  ELAVL1  mRNA  (embryonic  lethal,
abnormal  vision,  Drosophila-like  1),  human  Actb  (Beta-actin)  and  GAPDH  mRNA
(Glyceraldehyde-3-Phosphate Dehydrogenase) (Fig. 8).
The genomic 18S biodistribution pattern (Fig. 8, lower panel) displayed a homogeneous
expression across the mouse whole-body section. Interestingly, the 18S genomic signals
in the tumor region were significantly higher compared to the rest of the section. This
signal  increase  can  be  explained  by  the  fact  that  the  18S  qPCR  reagents  were  not
designed  to  discriminate  between  human  and  murine  18S  genomic  sequences.  This
results  in  qPCR signals  which  are  the  sum of  both  murine  and human genomic  18S
signals in the tumor region which does not only contain tissues originating from the tumor
but also murine endothelial tissues. This is why the elevated 18S signals might simply be
due to a very high cell density in the tumor region, combining cells from human and murine
origin.
Figure 8: Detection of a human tumor in a mouse whole-body section using RT-qPCR primers against human mRNAs.
The eye (E), brain (B), liver (Li) and gastro-intestinal tract (GI) are indicated in the top panel where the tumor (Tu) is
highlighted
The signals obtained for  the human mRNAs on the other  hand,  showed a strong co-
localization with the tumor region, corresponding to our expectancies. The diffuse signal
observed in the close vicinity of the tumor does not represent signal leakage, but is rather
an artifact generated by the imaging software (Fig. 9).
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Figure 9: Impact of the signal smoothing on the human ELAVL1 mRNA biodistribution pattern
The imaging software is converting every data point from the spreadsheet software in a
pixel. At the same time, the software generates a color gradient based on the maximum
and minimum relative expression signals measured by WBS-PCR. This color scale is then
used to attribute a color to every pixel (Fig. 9, upper panel). In order to generate the heat
maps shown previously,  the  TissueView™ software  is  then smoothing out  the signals
obtained  for  each  pixel,  therefore  generating  these  “leaking”  patterns  (Fig.  9,  middle
panel).  Although this  representation  might  not  be  perfect  because of  these “leaks”,  it
remains the best way to represent this type of data, and in the case of severe doubts on
the presence  of  signal  in  a  given  area,  it  is  always  possible  to  go  back  to  the  pixel
visualization, allowing a closer examination of the data.
In  summary,  we  successfully  identified  a  sample  preparation  method  compatible  with
WBS-PCR with the use of OTX Lysis Buffer. This allows not only the detection of coding
mRNAs, but also of genomic signals enabling “per-cell”  normalization of the RT-qPCR
signals, rather than using 18S rRNA as a normalizer, which can induce biases depending
on the translational  activity  of  a  given organs or  groups of  cells.  We also identified a
visualization  method  enabling  to  appreciate  the  biodistribution  of  any  oligonucleotide
detected by WBS-PCR.
C. Whole body Scanning PCR for the localization of miRNAs and 
siRNAs
As a next step, we sought out to investigate the in vivo biodistribution patterns of siRNAs
by WBS-PCR. In contrast to mRNAs assays, for which Taqman-based RT-qPCR assays
were  commercially  available,  there  were  no  commercially  available  assays  for  the
detection of siRNAs. We therefore developed an assay in-house, which we first validated
on miRNAs. Indeed, since miRNAs and siRNAs are highly similar, displaying sizes varying
from 19 to 23 nucleotides, their detection by RT-qPCR faces similar challenges.
C.1. Development of a RT-qPCR method for the detection of miRNAs 
and siRNAs
C.1.a) Molecular mechanism of the assay
The RT-qPCR assays used for the detection of mRNAs in previous experiments were
based on the combination of two primers and the hydrolysis of a Taqman probe. This
system can be applied to the detection of miRNAs and siRNAs only if the assay allows the
extension of the cDNA to generate enough room for the probe to bind to the amplicon,
since the target sequences are only around 20 nucleotides long. We nevertheless adopted
another strategy and designed an assay combining the use of primers displaying short
target recognition sequences (TRS) (76) with the use of a fluorescently labeled primer in
association with a quencher-labeled anti-primer (77).
Figure 10: Molecular mechanism of the miRNA RT-qPCR method
As for a RT-qPCR on mRNAs, the first step of the reaction consists in converting the RNA
template to a cDNA with the help of the Reverse Transcription (RT) primer (Fig. 10a). After
having been heated to inactivate the reverse transcriptase, the RT-mix is supplemented
with a qPCR-mix containing amongst other reagents a 5’-end fluorescently labeled forward
primer, as well as a 3’-end quencher labeled anti-primer, and a reverse primer, identical to
the  Reverse  Transcription  primer.  While  non-incorporated  forward  primers  will  be
quenched by hybridizing to the anti-primers, the fluorescence signal emitted by forward
primers involved in the amplification of the cDNA is monitored during the extension cycle
of the qPCR. An exponential increase of the fluorescence signals indicates the successful
amplification of the target (Fig. 10b).
C.1.b) Importance of the TRS length for optimal amplification
Unlike conventional mRNAs Taqman assays in which the full length of a primer encodes
for the TRS, the small size of a miRNA reduces dramatically the TRS size that can be
incorporated to a primer. In order to define the optimal TRS length that could be employed
for the detection of a synthetic miR-16-5p, we performed a small study in which we tested
a panel of RT/Reverse primers displaying various TRS lengths, and did the same with a
panel of forward primers displaying various TRS lengths (Fig. 11). Since temperature and
primer length are critical parameters for successful amplification (78), we should be able to
identify an optimal TRS length range for both the RT/Reverse and forward primers. We not
only  tested the  optimal  TRS length  of  the  RT/Reverse primer  (Fig.  11a)  but  we  also
determined the optimal TRS length of the forward primer (Fig. 11b). The length of the TRS
of the RT/Reverse primer has a big impact on the efficient detection of synthetic miR-16-
5p, and the amplification efficiency was assessed by comparing the sensitivity and linearity
achieved by using any of the primers tested.
Indeed, although there is an optimal TRS length of 7 nucleotides, a longer TRS does not
necessarily increase the quality of the amplification. However,  the maximum impact on
amplification is observed when shortening the TRS, since TRS shortening decreases the
sensitivity of the assay, but also hinders the linearity of the assay. The same study was
performed on the TRS of the forward primer,  and the results  obtained for the forward
primer  were  different  in  that  the  TRS length  does not  have  such a  strong impact  on
amplification efficacy as the TRS length of the RT/Reverse primer. Apart from the 9- and
10-mer  TRS  primers,  all  forward  primers  displayed  similar  amplification  efficiency,
therefore allowing more liberty in the design of the forward primer.
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Figure 11: Impact of the TRS length of the RT/Reverse (a) and forward primer (b) on the amplification efficiency of miR-
16-5p. Values are averages of four measurements, error bars, STDEV (n=4)
This study demonstrated that the design of the primers is absolutely crucial for efficient
amplification of a miRNA, the most critical part being the design of the reverse primers.
This can however be of a great advantage for the specificity of the assay.  An optimal
amplification can be observed for a given TRS length and amplification temperature. Thus,
in the case of a mismatch between two homologous sequences, when using the same
primers, the sequence containing the mismatch will  have an artificially shortened TRS.
This  can  have  a  dramatic  impact  on  the  amplification  efficacy,  allowing  to  generate
reagents  able  to  discriminate  between  highly  homologous  sequences,  and  therefore
design highly specific primers. This can be particularly interesting in the case of the Let-7
family of miRNAs for example, in which all miRNAs show highly homologous sequences.
C.1.c) Characterization of the RT-qPCR assay on the Let-7 family 
of miRNAs
Figure 12: Members of the Let-7 family of miRNAs, sorted by sequence homology to Let-7a.
Sequence variations are indicated in red
The sensitivity and specificity of this RT-qPCR method was tested using miRNAs of the
highly homologous Let-7 family.  The members of this family of  miRNAs display highly
homologous sequences, in some cases varying by only one nucleotide (Fig. 12) making it
therefore an ideal case study for our RT-qPCR method.
Figure 13: Verification of the specificity of the RT-qPCR method on members
of the Let-7 family of miRNAs. Error bars, STDEV (n=4)
First  we  addressed the  cross-reactivity  of  the  various  primer  pairs  by  performing  RT-
qPCRs on samples spiked with 2 pg of each miRNA target (Fig.  13).  The results are
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shown as % relative expression, where the perfect matches between targets and reagents
have been set to 100%. All of the reagents display 100% specificity towards their targets
whereas the background levels identified by NTC (No Template Control) did not show any
reactivity.  However in the case of Let-7a and Let-7c, a cross-reactivity of 3% could be
observed towards Let-7d and Let-7b, respectively.  This level of  cross-reactivity can be
explained by  the  fact  that  these targets  differ  only  by one nucleotide,  and this  single
mutation is located at the 3’-end of the Reverse primer TRS, therefore suggesting that the
primers were able to bind to these targets, although with a significantly reduced affinity
than  towards  their  perfect  match.  These  results  confirm  the  ability  of  our  method  to
perfectly discriminate highly homologous miRNAs which show at least 2 mismatches with
each other, and to significantly discriminate sequences differing by only one nucleotide.
Figure 14: Comparison of primers specificity achieved by the miRCURY LNA RT-qPCR method and our in-house
developed RT-qPCR assay. a: Molecular mechanism of the miRCURY LNA RT-qPCR. Primers specificity obtained by
using the miRCURY LNA RT-qPCR assay (b) or by our own RT-qPCR method (c)
Interestingly  our  results  are  very  similar  to  identical  experiments  published  by  Exiqon
showing results obtained with the miRCURY LNA-based miRNA RT-qPCR method (Fig.
14). This assay is based on the use of short PCR primers using Locked Nucleic Acids
(LNA) building blocks (Fig. 2) since the higher Tm of LNA-DNA duplexes allows the use of
shorter primers for the detection of miRNAs (Fig. 14a). Briefly, the target miRNA is first
poly-adenylated,  and is converted to a cDNA. This cDNA is subsequently amplified by
short LNA PCR primers and detected by using SYBR Green.
The results obtained in panel b and c of figure 14 indicate that our miRNA RT-qPCR assay
displays a specificity level similar to the one achieved by this commercially available assay
(79).
     
Figure 15: Characterization of the Taqman miRNA Stem-Loop RT-qPCR method. (a) Molecular mechanism of the
Taqman-based stem-loop RT-qPCR. (b) Specificity of the Stem-Loop RT-qPCR tested on the Let-7 family of miRNAs
Another  company,  called  Applied  Biosystems,  offers  commercially  available  miRNAs
quantification kits based on stem-loop RT-qPCR and using Taqman probes (Fig. 15a).
According  to  the  characterization  of  this  miRNA  Taqman  assay  (Fig.  15b),  the
performance of our assay is highly similar to results obtained by using these stem-loop
RT-qPCR-based assays (52).
Figure 16: Standard curves prepared with members of the Let-7 family of miRNAs. Values are averages of 4
measurements. Error bars, STDEV (n=4)
We subsequently set out to determine the sensitivity levels achievable by our assay, by
performing RT-qPCR assays  on standard curves prepared with  members of  the Let-7
family of miRNAs. The assays displayed linear standard curves over 8 to 9 logs with a R2-
linearity coefficient higher than 0.99 in all cases (Fig. 16). Furthermore, in most cases our
RT-qPCR method allowed us to detect as little as 0.02 fg template. However, in some
cases  sensitivity  was  as  low  as  0.002  fg  of  Let-7a  and  Let-7e,  corresponding  to
approximately 1640 and 164 target molecules, respectively.
Taken  together,  these  data  suggest  that  we  developed  an  efficient  assay  to  detect
miRNAs by RT-qPCR, which is very specific and highly sensitive.
C.1.d) Validation of the miRNA RT-qPCR method on tissue-
enriched non-coding miRNAs
To further validate the RT-qPCR method we performed a small study and investigated the
relative expression levels of a small panel of well characterized tissue-enriched miRNAs in
tissue homogenates described previously (Fig. 17a).
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Figure 17: Screening of a small panel of miRNAs in tissue lysates (a) and confirmation of the biodistribution of a sub-
fraction of the same panel of miRNAs in total RNA purified from tissues (b)
Not surprisingly we could clearly detect the extensively studied heart- and skeletal muscle-
specific miRNAs, miR-208a, miR-1a and miR-133a. Interestingly we could not only detect
miR-133a-3p but  also its  complementary sequence,  namely miR-133a-5p in  heart  and
skeletal muscle. The well characterized liver-specific miR-122 could be detected in liver,
whereas a panel of brain-enriched miRNAs could be found in brain, such as miR-124,
miR-127, miR-128, miR-132, miR-137 as well as miR-139 (80-82). The results obtained in
tissue lysates could be confirmed on total RNA purified from tissues using a smaller panel
of miRNAs including miR-122, miR-208a, miR-124-3p, miR-124-5p, miR-16 and miR-191
(Fig. 17b). The expression patterns obtained for both the tissue lysates and total RNAs
are similar for all miRNAs, except for miR-16 and miR-191. Although these miRNAs show
a similar trend indicating a broad expression pattern, small differences in signal intensities
could  be  observed.  This  can  be  explained  by  the  same  reason  which  led  to  signal
differences in mRNA detection (See section IV.B.1), namely that the relative expression
signals obtained from total RNA extracts were normalized using 18S rRNA and the input
concentration were all set to 10 ng/uL prior to RT-qPCR, whereas the relative expression
signals  obtained  from  tissues  lysates  were  normalized  only  by  using  the  18S  rRNA
expression  signals.  The possibility  to  detect  tissue-specific  miRNAs in  the  appropriate
samples confirms the compatibility of our miRNA RT-qPCR method with the OTX Lysis
Buffer, and its possible application in WBS-PCR.
C.2. Validation of the WBS-PCR by unraveling the in vivo 
biodistribution of small RNAs
C.2.a) Tissue-enriched non-coding miRNAs
(C.2.a.1) Endogenous non coding miRNAs
We validated the possibility to combine WBS-PCR with our in-house developed miRNA
RT-qPCR assay by determining the biodistribution pattern of a small  panel of miRNAs
(Fig. 17b) in mouse whole body sections (Fig. 18).
Figure 18: Biodistribution studies of miRNAs in mouse whole body sections by WBS-PCR. Organs indicated are brain
(B), liver (Li), heart (H), stomach (St) and gastro-intestinal tract (GI)
First,  the  efficiency  of  the  extraction  procedure  was  confirmed  by  determining  the
biodistribution of genomic 18S (Fig. 18, lower panel) which displayed a homogeneous
pattern and was used to normalize the miRNAs relative expression data.
The biodistribution study performed on miR-122-5p, miR-208a-3p, miR-124-3p, miR-124-
5p, miR-191-5p and miR-16-5p resulted in the same biodistribution pattern as the one
observed in tissue homogenates, namely that miR-122-5p co-localized with liver, miR-208-
3p with the region of the heart, whereas miR-124-3p and miR-124-5p, both generated from
the same pre-miRNA, co-localized with  brain.  miR-16-5p and miR-191-5p on the other
hand showed quite a homogeneous biodistribution pattern, as expected from data shown
previously.
In summary, this data clearly indicates that our miRNA RT-qPCR is compatible with the
tissue-specific  detection  of  miRNA  in  tissue  homogenates  prepared  for  WBS-PCR.
Moreover, similar data could be generated by applying the miRNA RT-qPCR method to
WBS-PCR, suggesting that it is indeed possible to detect miRNAs in mouse whole body
sections by combining both assays.
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(C.2.a.2) Ectopic non-coding miRNAs
Figure 19: Detection of a human tumor in a mouse whole-body section using RT-qPCR primers against human non
coding miRNAs. The eye (E), brain (B), liver (Li) and gastro-intestinal tract (GI) are indicated in the top panel where the
tumor (Tu) is highlighted
Following  the  successful  detection  of  tissue-enriched  endogenous  miRNAs,  we
investigated the possibility to detect ectopic miRNAs in a mouse tumor model, namely the
HCT-116  tumor.  We therefore  developed  and  characterized  reagents  against  human-
specific miRNAs which should only be expressed in human cells, and be absent from the
surrounding mouse tissues, namely miR-197-3p and miR-769-3p (83-85) (Fig. 19).
The  genomic  18S  relative  expression  in  the  mouse  whole  body  section  is  quite
homogenous across the section (Fig. 19, lower panel), although showing elevated signal
intensities in the region of the tumor. Both miRNAs, namely miR-197-3p and miR-769-3p,
show a highly localized biodistribution pattern in the tumor region, as expected for the
detection of a human-specific miRNA. The biodistribution obtained for miR-16-5p on the
other hand, showed a uniform pattern across the section, since this miRNA is identical in
human and murine cells.
This dataset once more confirms the resolution that can be achieved by using WBS-PCR
as well as the specificity level of our miRNA RT-qPCR method.
C.2.b) Validation of the WBS-PCR for the detection of a locally 
injected siRNA
Figure 20: Biodistribution study of a locally injected siRNA. Upper panel: Color pictures of the either siRNA- or PBS-
injected mice. The injection sites are highlighted by the presence of Light Green in the injected solutions (black arrows).
Lower panel: WBS-PCR results obtained for genomic 18S or SSB siRNA in the siRNA-injected mouse (left panel) or in
the PBS-injected mouse (right panel)
To validate the WBS-PCR for siRNA detection, we performed a biodistribution study on a
locally injected siRNA and its subsequent detection by WBS-PCR. We therefore sacrificed
two  mice,  and injected either  an  SSB siRNA or  a  PBS solution  into  the  brain  of  the
animals, and subjected both animals to deep-freezing right after the injection to minimize
the diffusion of the solutions into surrounding tissues. In order to locate the injection sites
during  mouse  sectioning,  Light  Green  Dye  was  added  to  both  the  siRNA  and  PBS
solutions (Fig. 19b). The quantification of the siRNA in the sections was made possible by
subjecting a standard curve prepared with siRNA to RT-qPCR, allowing to determine the
amount of siRNA present in a well based on the Ct-value obtained in this well (Fig. 20a).
After sectioning, pictures of the mice were taken to locate precisely the injection sites by
monitoring the intensity of the green dye present in the injected solution (Fig. 20b, upper
panels, black arrows). As expected, Light Green Dye was visible in the brain, and in a
lesser extend in the cerebrospinal fluid, located between the brain and the skull  in the
siRNA-injected animal (Fig. 20b, upper left panel). WBS-PCR results obtained for this
section confirmed the presence of the siRNA in the brain (Fig. 20b, lower left panel).
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Subjecting a section of the PBS-injected animal  to similar analytics  resulted in slightly
different results. Although Light Green Dye could also be seen in the brain of the PBS-
injected animal, in a small cavity located in the center of the brain (Fig. 20b, upper right
panel), no signal was generated by WBS-PCR, confirming the absence of siRNA in this
section (Fig. 20b, lower right panel).
According to  the results  obtained for this  study,  we can conclude that  WBS-PCR can
successfully be used for the detection of siRNAs in mouse whole body sections, when
injected locally.
C.2.c) In vivo biodistribution study of an intravenously injected 
unformulated siRNA
(C.2.c.1) Detection of a siRNA in a mouse whole body 
section by WBS-PCR and QWBA
To further  validate  our  WBS-PCR for  siRNA detection,  we  performed a biodistribution
study on a tritium labeled siRNA targeting the rat Multi-drug Resistance Protein 4 (Mrp4)
intravenously injected in mouse monitored by either the conventional QWBA method (60),
or by our WBS-PCR method.
Although we could already show that the RT-qPCR assay that we validated on miRNAs
was also applicable to the detection of siRNAs (Fig. 20), we had to make sure that the
Mrp4 siRNA could be detected with a similar efficacy, that is why we performed a RT-
qPCR on a standard curve prepared with the aforementioned Mrp4 siRNA (Fig. 21a). The
assay displayed a standard curve linear over 6 logs, with a R2-value higher than 0.99, and
allowing the detection of as little as 2 fg siRNA.
The Mrp4 siRNA used in this study was tritium-labeled by Christensen et al (86), favoring a
tritiated Uridine located in the middle of the oligonucleotide. This particular labeling was
selected because of the lower isotope exchange rate of an oligonucleotide tritiated at a
single  position  compared  to  a  fully  radiolabeled  backbone,  using  a  fully  32P-labeled
backbone for example. Furthermore, the central location of this isotope was motivated by
the fact that a radiolabeled nucleotide located near the 5’- or 3’-end of the oligonucleotide
would  be cleaved off  by endonucleases much faster  than a  nucleotide  located in  the
middle of the sequence. The mouse was sacrificed 10 minutes post-injection, deep frozen
and subsequently sectioned. While one section was analyzed by QWBA, a neighboring
section was analyzed by WBS-PCR.
Figure 21: Detection of the Mrp4 siRNA by combining siRNA RT-qPCR and WBS-PCR. Mrp4 standard curve (a) and in
vivo biodistribution of the unformulated Mrp4 siRNA (b) analyzed by Quantitative Whole Body Autoradiography (QWBA)
and WBS-PCR (Mrp4 siRNA). Tissues indicated are brain (B), salivary gland (Sg), heart (H), liver (Li), blood vessel
(Bv), kidney (K) and gastro-intestinal tract (GI)
The profile obtained for the siRNA biodistribution 10 minutes post-injection by QWBA (Fig.
21b, QWBA) indicates high levels of radioactivity in white in the kidney and in the salivary
gland as well  as in liver albeit  in lower levels.  The WBS-PCR results obtained for the
biodistribution of the Mrp4 siRNA (Fig. 21b, Mrp4 siRNA) showed elevated siRNA levels
in the kidney, liver and blood vessel. The presence of siRNAs in blood vessel could be
explained by the fact that the animal was sacrificed only 10 minutes post-injection, thereby
limiting its metabolization, while the presence of the siRNA in liver and kidney corroborated
data generated by QWBA. Very surprisingly, we could not detect any siRNA in the salivary
gland by WBS-PCR, although data generated by QWBA clearly indicates the presence of
radioactive material. The fact that we failed to detect any siRNA in this organ could not be
explained by poor extraction efficiency, since genomic 18S and miR-191-5p were clearly
present in the salivary gland according to WBS-PCR (Fig. 21b, lower panels). 
(C.2.c.2) Detection of siRNA metabolites by RT-qPCR and 
LC-MS
Given the short half-life of unformulated siRNAs in mouse plasma, we hypothesized that
the radioactive signals observed in the salivary gland by QWBA were the result of the
accumulation of by-products of the metabolization of the siRNA in the salivary gland. To
confirm this assumption we performed RT-qPCRs on standard curves prepared with 5’-
end, 3’-end or both ends truncated siRNA, in order to mimic the in vivo metabolization of
the siRNA (Fig. 22).
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Figure 22: Lower limits of detection obtained for truncated versions of the Mrp4 siRNA by RT-qPCR. Values are
averages of 3 measurements. Error bars, STDEV (n=3)
In order to compare the amplification efficiency obtained for each truncated template, we
performed  RT-qPCRs  on  standard  curves  prepared  with  every  truncated  siRNA,  and
determined the lower limit of detection achievable for each of these truncated templates.
The lower limit of detection obtained for the full-length Mrp4 siRNA was close to 2 ag, and
we used this value as a reference for all truncated siRNA versions. The 3’-end truncations
(Fig. 22, upper panel) seemed to be tolerated by our assay up to 3 nucleotides, at which
point the lower limit of detection was increased up to 10,000-fold, indicating a far less
efficient amplification. The 5’-end truncations on the other hand (Fig. 22, middle panel),
displayed a much more gradual effect on RT-qPCR sensitivity, since the truncation of 3
nucleotides at the 5’-end of the siRNA resulted in a 10-fold increase of the lower limit of
detection. The loss of 4 and 5 nucleotides resulted however in a 1,000- and 10,000-fold
decrease  in  sensitivity,  respectively,  indicating  a  severe  drop  of  sensitivity.  The
concomitant truncation of both ends of the siRNA however, displayed much more severe
impacts on the lower limit of detection of the RT-qPCR assay (Fig. 22, lower panel). The
truncation of only one base at both sides of the siRNA resulted in a 100-fold higher lower
limit  of  detection,  and the lower  limit  of  detection increased dramatically the more the
siRNA was  truncated.  This  therefore leads to  a shift  of  the lower  limit  of  detection of
truncated siRNAs, indicating that the more an siRNA will be truncated, the less efficient its
detection by RT-qPCR will  be,  and will  ultimately  be undetectable by RT-qPCR if  the
truncation is too advanced. When considering the siRNA detection in the mouse whole
body section (Fig. 21b), where the average siRNA amount is 10 fg siRNA, only a limited
panel  of  truncated  siRNAs  can  be  detected,  displaying  a  maximum  of  2  nucleotides
truncations at the 3’-end, 3 nucleotides at the 5’-end, or 1 nucleotide at each end of the
siRNA,  and  of  course  the  full  length  siRNA.  With  WBS-PCR  we  therefore  have  the
possibility  to  detect  only  full-length  or  slightly  metabolized  siRNAs.  Over  time,  and  if
metabolization of the siRNA is going on, the siRNA will be undetectable by RT-qPCR, a
phenomenon which we observed in this study, since we were unable to detect any siRNA
in a section of a mouse sacrificed 1 hour post-injection, whereas QWBA clearly showed
presence of the Mrp4 siRNA.
To further identify the source of the radioactivity detected in the salivary gland by QWBA,
we subjected pieces of salivary gland cut out of QWBA sections to LC-MS analysis (Fig.
23).
The radioactivity level of the sample was monitored during the LC-MS run and allowed to
identify  a  few radioactive  moieties.  Unfortunately,  only  one of  the peaks contained an
identifiable moiety, namely the peak annotated M1 (Fig. 23, red square), corresponding to
radio-labeled mono-uridine. Although the other peaks (annotated Px.x, where x.x indicates
their retention time) also showed a certain level of radioactivity, their exact structure could
not be identified by MS, since their mass did not correspond to the mass of expected
metabolization products.
Figure 23: LC-MS analysis of the radioactively-labeled content of the salivary gland of a mouse sacrificed 10 minutes
post-injection
Neither full-length, nor truncated oligonucleotides could be identified in this experiment,
indicating the high level of metabolization of the Mrp4 siRNA in the salivary gland.
In summary,  we showed that the miRNA RT-qPCR assay that we developed in house
could successfully be used for the quantification of siRNAs. Moreover, similar conclusions
could be drawn by using either WBS-PCR or QWBA, known as a standard method used
for siRNAs in vivo biodistribution studies.
D. Whole Body Scanning qPCR for the in vivo localization of heavily 
chemically modified oligonucleotides
Therapeutic siRNAs are used for their ability to regulate the expression of coding mRNAs,
and their mechanism of action which is similar to the one of cellular miRNAs. In some
diseases such as cancer for example, a battery of miRNAs called oncogenic miRNAs can
be expressed at elevated levels compared to healthy patients. That is why another class of
therapeutic  oligonucleotides  has  been  developed  to  target  these  miRNAs,  called
antagomirs or Anti-miRNA-oligonucleotides (AMO). It has already been shown that these
antagomirs  are  biologically  active  towards  their  targets  and  open  up  new  treatment
possibilities (87). The AMO-miR-221 for example has been shown to significantly increase
tumor doubling time, and to increase the life span of tumor mouse models (88). Such an
AMO  has  however  to  be  chemically  modified  to  display  higher  resistance  towards
nucleases, as well as higher binding efficiencies towards RNA molecules, to increase its
cellular uptake and to display better pharmacokinetic and pharmacodynamics properties
(62,63).
D.1. Development of Chemical Ligation qPCR (CL-qPCR), a method 
for the detection of heavily chemically modified oligonucleotides
D.1.a) The need for a detection method for heavily chemically 
modified oligonucleotides
The growing interest in using antagomirs as therapeutic oligonucleotides (24) and their
heavy chemical modifications prompted us to test the possibility to study the biodistribution
pattern  of  such  entities  in  vivo using  WBS-PCR.  We  therefore  used  our  in-house
developed miRNA/siRNA RT-qPCR method to detect an antagomir targeting miR-16-5p
(AMO-miR-16)  available  in  three  different  chemical  formats,  namely  RNA,  2’O-methyl
(2’Ome) and the 2’-O-methoxy-etoxyethyl (MOE) (Fig. 24).
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Figure 24: RT-qPCR detection of AMO-miR-16 in three different chemical formats, RNA (a), 2’Ome (b), and 2’MOE (c).
Values are averages of 4 measurements. Error bars, STDEV (n=4)
By using our in-house developed miRNA/siRNA RT-qPCR method we could, as expected,
detect the RNA-synthesized AMO-miR-16 (Fig. 24a). Surprisingly,  we could also detect
the 2’-OMe-modified AMO-miR-16 (Fig. 24b), though the sensitivity was reduced by 10-
fold compared to the RNA-synthesized AMO-miR-16. The MOE-modified AMO-miR-16 on
the contrary, could not be detected at all by using this RT-qPCR method (Fig. 24c).
We therefore had to develop an assay able to detect oligonucleotides independent from
their chemical format.
D.1.b) Molecular mechanism of the CL-qPCR
As could be seen in figure 2, the 2’-OMe and 2’-MOE chemical modifications only affect
the  oligonucleotide  backbone,  leaving  the  nitrogen  bases  unaffected.  Although  these
modifications interfere with enzymes such as Reverse Transcriptase and Taq Polymerase,
the antagomir is still perfectly able to hybridize to any other oligonucleotides.
The crucial step in this assay is to convert the antagomir in a DNA molecule amplifiable by
Taq Polymerase. Since Reverse Transcriptase is not able to generate a cDNA from such a
template, we developed a qPCR assay based on a templated chemical ligation described
by Kool et al (89,90).
The assay we ought to develop uses the same qPCR strategy as the assay to detect
miRNAs and siRNAs, but  we replaced the enzymatic  Reverse Transcription step by a
chemical  ligation step (Fig.  25a).  The chemical ligation step is an alternative to cDNA
synthesis by reverse transcription, where two small ligators have the ability to hybridize to
the  target,  and  the  close  proximity  induced  by  hybridization  subsequently  allows  the
formation of a phosphorothioate bond between both ligators. The resulting ligated product
can subsequently be amplified and detected by qPCR.
Figure 25: Principle of the Chemical Ligation qPCR (CL-qPCR). Molecular mechanism of the CL-qPCR mediated
detection of a highly chemically modified template (a) and reaction between a PS-group and a BPS-leaving group,
generating a phosphorothioate linkage between both ligators (b)
Although  Kool  et  al  described  a  method  based  on  an  iodine-leaving  group  (91),  we
observed by quality check that this leaving group was lost when coupled with G- and C-
bases.  Although  the  iodine-group  could  be  efficiently  coupled  to  a  T-,  or  an  A-base,
coupling to a G- or C-base resulted in the iodine reacting with  the bases themselves,
therefore rendering these ligators non-usable for ligation. This high reactivity and the low
lipophilicity of iodine-coupled ligators did not enable them to be purified by using standard
cassette oligonucleotides purification methods. We later identified the BisPhenylSulfonyl
(BPS) moiety as an efficient alternative to the use of iodine. This BPS-leaving group works
in  a  similar  fashion  as  a  dabsyl-leaving  group  (92),  which  allows  the  formation  of  a
Phosphorothioate bond between both ligators in the case of an nucleophilic attack by a
Phosphorothioate group on the leaving group (Fig. 25b). Furthermore, the lipophilicity of
the BPS-leaving group allows efficient purification of the ligator using standard cassette
purification methods, allowing a better quality control of the generated reagents.
D.1.c) Optimization of the synthesis conditions
The generation of highly pure reagents is crucial  to develop an efficient assay.  It  can
indeed be very harmful to the assay if  a fraction of the reagents does not display the
appropriate 3’-PS or 5’-leaving group, since these reagents would be able to bind to their
targets, but unable to react and to generate an amplifiable ligated product. That is why we
subjected our ligators to LC-MS analysis to check for reagents purity and integrity (Fig.
26). The LC-profile obtained for the PS-ligator (Fig. 26a, left panel) showed a single peak
at 3.11 seconds. The mass calculated for the PS-ligator was of 6133.192 Da (Fig. 26a,
right  panel),  and the mass obtained for  the molecule present  in  the LC-peak was  of
6132.95 Da, allowing us to conclude that this peak indeed corresponded to the PS-ligator.
Figure 26: LC-MS analyses performed on the AMO-miR-16 PS-ligator (a) and BPS-ligator (b)
The LC profile obtained for the BPS-ligator on the other hand showed two peaks at 3.42
and 4.06 seconds (Fig.  26b,  upper panel).  The 3.42 peak was analyzed by MS and
showed the presence of a 6471.25 Da (Fig. 26b, lower left panel) whereas the mass
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calculated for the BPS-ligator was of 6688.398 Da. Very surprisingly, the major LC-peak
did not contain the intact BPS-ligator. We therefore analyzed the secondary peak located
at 4.06 seconds, and could identify a molecule displaying a mass of 6688.35 Da (Fig. 26b,
lower right panel), therefore corresponding to the intact BPS-ligator. We subsequently
investigated the nature of the molecule eluted at 3.42 seconds, and after having calculated
the mass of the BPS-leaving group, we could conclude that the difference between the
calculated and obtained mass in this peak corresponded to 217 Da, the mass of the BPS-
leaving group. This led us to the conclusion that the BPS-ligator solution did not consist of
only intact BPS-ligator, but contained only 10% intact BPS-ligator, whereas the other 90%
corresponded to BPS-free BPS-ligator.
We identified the deprotection reagents and conditions as the initiators of the BPS-group
cleavage  from  the  BPS-ligator.  The  use  of  soft  deprotection  reagents  (Ultramild  CE
phosphoramidites) as well  as soft  deprotection conditions by shortening the incubation
time from an overnight to a 4 hours incubation time, as well as performing this reaction at
room temperature rather  than at  50°C led to  the synthesis  of  a  second generation of
ligators which were subjected to LC-MS studies as well (Fig. 27).
Figure 27: LC-MS analyses of the AMO-miR-16 PS-ligator (a) and BPS-ligator (b) generated under optimal synthesis
conditions
The LC-MS analysis provided us this time results confirming the presence of intact PS-
ligators (Fig. 27a) and BPS-ligators (Fig. 27b) since the expected and obtained masses
were similar in both cases.
D.1.d) Validation of the CL-qPCR assay
Figure 28: CL-qPCR detection of AMO-miR-16 in three different chemical formats, RNA (a), 2’Ome (b), and 2’MOE (c).
Values are averages of 4 measurements. Error bars, STDEV (n=4)
The performance of this assay was assessed by detecting AMO-miR-16 in three different
chemical formats (Fig. 28).  Not surprisingly,  similar results were obtained on the three
chemical formats tested, since we could detect down to 20 fg AMO-miR-16 when present
in RNA (Fig. 28a) and 2’-Ome formats (Fig. 28b), and as little as 2 fg when present in 2’-
MOE (Fig. 28c).
Showing that we could actually detect a 2’-MOE modified oligonucleotide was a big step
forward in the validation process of our CL-qPCR method. As a next step however, we
wanted to show that the BPS-leaving group could be coupled to any base. CL-qPCR was
therefore  performed with  ligators  containing  either  a  5’-BPS-T,  -G,  -C,  or  –A,  for  the
detection of synthetically generated variants of the AMO-miR-16 sequence (Fig. 29).
Figure 29: CL-qPCR on mutated versions of the AMO-miR-16 antagomir. Values are averages of 4 measurements.
Error bars, STDEV (n=4)
In each graph the sequences of the AMO-miR-16 variants and both ligators are indicated.
The template sequence is shown on top, and the mutation is indicated in red. The ligators
are also indicated, and the base coupled to the BPS-leaving group is indicated in red,
underlined. The assay displayed similar results in all cases, with standard curves linear
across 6 logs and allowing the detection of as little as 20 fg template.
This result indicates that the assay performs with similar efficiency independent from which
base the BPS-leaving group was coupled to.
D.2. In vivo biodistribution study of AMO-miR-16, an MOE-modified 
anti-miRNA-oligonucleotide targeting miR-16-5p
D.2.a) Validation of the compatibility of CL-qPCR with WBS-PCR 
for the detection of a locally injected AMO-miR-16 antagomir
To assess whether CL-qPCR could be used in combination with WBS-PCR, we performed
a biodistribution study on a locally injected AMO-miR-16 and its subsequent detection by
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WBS-PCR. We therefore sacrificed two mice, and injected either AMO-miR-16 or a PBS
solution into the brain of the animals, and subjected both animals to deep-freezing right
after the injection to minimize the diffusion of the solutions into surrounding tissues. In
order to locate the injection sites during mouse sectioning,  we supplemented both the
AMO-miR-16 and PBS solutions with Light Green Dye, and we checked by WBS-PCR
whether AMO-miR-16 could be detected in the appropriate regions.
Figure 30: Biodistribution study of a locally injected antagomir. Upper panel: Color pictures of the either AMO-miR-16-
or PBS-injected mice. The injection sites are highlighted by the presence of Light Green in the injected solutions (black
arrows). Lower panel: WBS-PCR results obtained for genomic 18S or AMO-miR-16 in the AMO-miR-16-injected mouse
(left panel) or in the PBS-injected mouse (right panel)
The injection sites in the sections of the AMO-miR-16- and PBS-treated animals were
located using the Light Green dye present in the injected solutions (Fig. 30, upper panel,
black arrows). The PBS-treated animal displayed an area containing green dye in a small
cavity in the brain whereas the AMO-miR-16 could be detected in various places in the
brain  of  the  AMO-miR-16 treated animal,  as  well  as  in  the  cerebrospinal  fluid  of  this
animal, not only highlighting the space between the brain and the skull of the animal, but
also highlighting a small region along the spinal cord.
We performed subsequently a CL-qPCR on the lysates obtained from the lysis of both
mouse sections (Fig. 30, lower panel). The biodistribution pattern obtained for the AMO-
miR-16-treated animal highlighted the regions containing green dye in the brain and along
the spinal cord of the animal, confirming the colocalization of the injected solution and
presence of the AMO-miR-16 antagomir. As expected, no AMO-miR-16 could be detected
in the brain of the PBS-treated animal.
This study confirms the possibility to use lysates generated for WBS-PCR as samples for
CL-qPCR, therefore allowing the detection of highly modified oligonucleotides in whole
body sections by combining WBS-PCR and CL-qPCR.
D.2.b) Monitoring AMO-miR-16 levels by CL-qPCR in mouse 
blood and tissues
In this study we tested how the CL-qPCR performed in an  in vivo biodistribution study
performed by either WBS-PCR or by the classical way of sampling various organs from the
animals. We injected 5 mice intravenously with 80 mg/kg AMO-miR-16, and 5 control mice
with PBS. Blood samples were taken from each single animal until 24 hours post-injection,
at which point the animals were sacrificed. After sacrifice, one mouse of each group was
deep-frozen,  sectioned  and  subjected  to  WBS-PCR,  while  the  other  animals  were
subjected to organ sampling.
  
  
Figure 31: Quantification of AMO-miR-16 by CL-qPCR in blood samples (a) and tissue homogenates (b), and RT-qPCR
detection of miR-16-5p (c) and miR-191-5p (d). Values are averages of triplicate measurements from 5 (a) or 4 animals
(b-d). Error bars, s.e.m. (n=15 (a), n=12(b-d)). *p<0.05 (Mann-Whitney Rank sum test (a-c), t-test (d), n.s.: not
significant)
No AMO-miR-16  could  be  detected  in  mouse  plasma  after  30  minutes  post-injection,
suggesting that the AMO-miR-16 was cleared from circulating blood (Fig. 31a).
We sampled a few representative organs such as brain, kidney, liver, lung and spleen from
4  mice  treated  with  PBS  and  4  mice  treated  with  AMO-miR-16.  We  subsequently
quantified  AMO-miR-16,  miR-16-5p  as  well  as  miR-191-5p  as  control  in  tissue
homogenates prepared from these organs and signals were  normalized against tissue
weight (Fig. 31b-d).
AMO-miR-16 could be detected in kidney and liver in relatively high levels, whereas lung
and spleen displayed levels 500 times lower than the ones found in kidney (Fig. 31b).
Very interestingly, no AMO-miR-16 could be detected in brain, neither in the PBS-treated
animals, nor in the AMO-miR-16 treated animals, suggesting that AMO-miR-16 does not
penetrate  the  blood-brain  barrier.  The  quantification  of  miR-16-5p  in  the  same  tissue
homogenates (Fig. 31c) resulted in far more elevated miR-16-5p levels in the PBS-treated
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animals than in the AMO-miR-16 treated animals. This was however not the case in the
brain in  which  no reduction of  miR-16-5p levels  could be observed.  We subsequently
measured miR-191-5p levels to make sure that the lower levels of miR-16-5p in the tissues
containing  AMO-miR-16 were  indeed due to  sequestration  of  miR-16 by AMO-miR-16
(Fig.  31d).  As  expected,  no  significant  differences  could  be  detected  in  miR-191-5p
relative expression levels between tissues isolated from PBS- and AMO-miR-16-treated
animals.
Taken  together,  these  data  strongly  suggest  that  our  CL-qPCR is  well  suited  for  the
efficient quantification of heavily chemically modified oligonucleotides in  in vivo studies
performed on sampled organs. As a next step, we evaluated the possibility to use WBS-
PCR for the detection of AMO-miR-16 injected intravenously and whether results obtained
using the classical way of organ sampling could be reproduced by WBS-PCR.
D.2.c) Biodistribution pattern of AMO-miR-16 using WBS-PCR in 
combination with CL-qPCR
We quantified AMO-miR-16 levels by CL-qPCR and miR-16-5p by RT-qPCR in mouse
whole body sections. Both datasets were normalized against genomic 18S (Fig. 32).
In  order  to  allow  direct  comparisons  between  both  mouse  sections,  signal  intensities
obtained for each gene were displayed using the same scale. First of all, we noticed that
the genomic 18S relative expression levels displayed similar signal intensities in both mice
(Fig.  32,  lower  panel),  indicating  similar  extraction  efficiencies  in  both  sections.  As
expected, we could only detect AMO-miR-16 in the AMO-miR-16 treated animal (Fig. 32,
left-hand side),  whereas no signal could be detected by CL-qPCR in the PBS-treated
animal (Fig. 32, right-hand side). The AMO-miR-16 biodistribution pattern indicated the
presence of mild levels of AMO-miR-16 in most organs of the treated mouse, and high
amounts of AMO-miR-16 in the kidney, and in a lesser extent in liver. Interestingly, we
could not detect any AMO-miR-16 in the brain region, an observation that was already
made on tissue lysates. Furthermore, these observations are in accordance with published
data using LC-MS measurements in organs sampled from a rat injected with a PO-MOE
modified  oligonucleotide  targeting  the  human  intercellular  adhesion  molecule-1  mRNA
(93).
We also investigated whether we could see a difference in miR-16-5p levels between both
animals,  and very  much to  our  surprise,  we  could  observe strikingly  lower  miR-16-5p
relative  expression  signals  across  the  section  of  the  AMO-miR-16  treated  animal,
compared to the PBS treated animal.  In addition to this,  there were still  a few organs
showing quite elevated miR-16-5p levels in the AMO-miR-16 treated animal, such as lung,
a blood vessel close to the salivary gland, liver, heart, and brain. In the case of the brain,
this could of course be explained by the absence of AMO-miR-16 in the brain as could
already be previously  seen  in  sampled organs.  The presence  of  miR-16 in  the  other
tissues could also be seen in the previous experiment, and although the bar graphs used
gave the impression of a complete knock-down of miR-16-5p, there was only a reduction
of the expression levels of this miRNA of approximately 50-fold, which explains why miR-
16-5p could be visualized in some tissues of the AMO-miR-16-treated mouse section.
Figure 32: AMO-miR-16 in vivo biodistribution monitored by CL-qPCR. The eye (E), brain (B), heart (H), lung (Lu), liver
(Li), stomach (St), kidney (K), gastro-intestinal tract (GI) and bone (Bo) are indicated on the Whole Body Section picture
(upper panel)
With this study we could show that (i) the CL-qPCR can be combined with WBS-PCR in
order to monitor the in vivo biodistribution of heavily chemically modified oligonucleotides,
and (ii) that WBS-PCR resulted in the same observations as the classical way of sampling
individual organs. 
E. Conclusion/Discussion
First  of  all,  the  miRNA RT-qPCR that  we  developed benefits  from many advantages.
Indeed, not only does this assay display similar characteristics to commercially available
assays in terms of sensitivity and specificity, but it also offers more flexibility to the user.
Reagents can easily be designed for any given target, without the need to disclose any
sequence  of  therapeutic  interest  to  the  companies  offering  to  generate  custom-made
reagents. Furthermore, the characterization of the reagents on a synthetic target can be
performed  in  a  relatively  easy  and  straight  forward  manner.  The  similarities  between
miRNA and siRNA design makes this assay compatible for the detection of siRNAs. The
truncation of the template sequence can nevertheless severely impact the sensitivity of the
RT-qPCR,  rendering  truncated  siRNAs  barely  detectable  by  RT-qPCR.  This  can  be
problematic for the detection of full-length oligonucleotides by WBS-PCR especially when
considering  the  fact  that  unformulated  and  non-modified  siRNAs  are  degraded  within
minutes in vivo (40). In the case of an unformulated or unmodified oligonucleotide, WBS-
PCR has to be performed no later than 10 minutes. Being able to detect full-length, and
therefore potentially biologically active siRNAs in  in vivo samples rather than truncated
molecules, can on the other hand be considered as an advantage. Despite this advantage,
it then becomes quite difficult to monitor the fate of a metabolized siRNA. As it can be
seen in  this  study,  radioactive  labeling does not  allow the discrimination between full-
length  and  metabolized  oligonucleotides,  but  is  a  very  powerful  method  to  provide
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information with respect to the location of full-length oligonucleotides and their metabolites.
The sum of information provided by both methods can be highly valuable, since it allows
the  identification  tissues  where  full-length  oligonucleotides  and  their  metabolites
accumulate (QWBA), and where full-length and therefore functional oligonucleotides might
display a biological function (WBS-PCR).
We  also  developed  an  assay  based  on  template  mediated  chemical  ligation  for  the
quantification  of  heavily  chemically  modified  oligonucleotides,  which  are  otherwise
undetectable by RT-qPCR. Although the sensitivity of this method seems to be a bit lower
than  the  sensitivity  achievable  by  RT-qPCR,  it  is  an  efficient  way  to  detect  chemical
formats  such  as  2’-MOE  modified  oligonucleotides,  which  are  incompatible  with
conventional  or  modified PCR enzymes (94).  This  method allows  the  quantification  of
oligonucleotides in a completely independent manner from the chemical format applied to
the oligonucleotides since it is based on DNA-RNA hybridization. Moreover, the coupling
of  chemical  ligation  with  a qPCR readout  allows  to  achieve a greater  sensitivity  level
compared to methods making use of other amplification methods such as rolling circle
amplification (95).
Last  but  not  least,  the  efficiency of  WBS-PCR could  be successfully  demonstrated  in
biodistribution studies of various RNA species such as mRNAs, miRNAs and siRNAs, as
well as heavily chemically modified oligonucleotides. Extraction procedures using tissue
sections overlaid on plates filled with lysis buffer have already been investigated by Armani
et al  and reported as 2D-RT-qPCR (96).  However,  unlike WBS-PCR, this method only
focuses on the sections of a few organs and not on whole body sections, therefore the
resolution offered by this method is not as high as the one offered by a 1536-well plate as
in the case of WBS-PCR. Furthermore, the extraction method described in this paper,
based on poly-T-coupled magnetic beads does not allow the recovery of all kinds of RNA
molecules,  as  well  as  the  recovery  of  genomic  material,  thereby  limiting  the  target
spectrum.
In  order  to  perform  WBS-PCR  studies,  it  was  also  crucial  to  determine  an  efficient
normalization  method  to  be  able  to  draw  conclusions  on  relative  quantifications  of
oligonucleotides. Unlike RNA purification with Trizol, the samples generated for WBS-PCR
could not be normalized on account of their RNA concentrations. Furthermore, the fact that
the  samples  covered a  whole  mouse section  did  not  allow the  use of  house-keeping
mRNAs  since  too  many  variations  could  be  introduced  by  the  various  cell  densities,
extraction efficiencies and translational status of various tissues.
We could also identify the WBS-PCR as an efficient method to unravel mRNAs expression
patterns, since the amount of information that can be obtained from one WBS-PCR run is
more  considerable  than  what  can  be  derived  from  RT-qPCR  runs  performed  on
individually isolated organs. A WBS-PCR run covers indeed all  the organs that can be
found in a mouse section, whereas RT-qPCRs on single organs are often biased by the
organs selected in the in vivo study.
Furthermore, not only were our WBS-PCR results comparable to results obtained with
QWBA,  but  the  observations  made  by  WBS-PCR  could  also  be  confirmed  in  tissue
homogenates, showing the high predictability potential of this method. Even if it can be
considered  as  yet  another  sampling  method,  one  WBS-PCR  run  provides  more
information  than  conventional  organ  sampling  since  with  5  whole  body  sections,  it  is
possible to cover every organ of a mouse body. Furthermore, the preparation procedure is
less harmful to the organs since the mice were deep-frozen right after sacrifice, preventing
the degradation of RNAs and siRNAs that could have occurred during conventional organs
sampling. The number of organs covered by a WBS-PCR run also allows the reduction of
biases induced by arbitrarily choosing organs to be sampled when performing an in vivo
biodistribution study on a compound with unknown homing characteristics. In that sense,
WBS-PCR  can  be  used  as  a  preliminary  characterization  step  to  define  the  homing
properties  of  a  therapeutic  oligonucleotide,  and  once  the  biodistribution  of  an
oligonucleotide has been unraveled, further  in vivo experiments can be focused on only
the organs in which the compound could be detected. The resolution of the WBS-PCR,
dictated  by  the  size  of  the  plates  used  for  lysis,  in  our  case  1536-well  plate,  is  not
competing yet with other methods such as in situ hybridization. However, such a format
can easily be automated using liquid handling robots, thereby increasing the throughput of
this method for the screening of novel oligonucleotides delivery methods with unknown
homing properties. WBS-PCR can therefore be of great help for the determination of the
biodistribution of siRNAs delivered using novel delivery vehicles (51).
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V. Evaluation of the potential use of exosomes as novel siRNA 
delivery vehicles
A. Introduction
As discussed previously,  efficient and tissue-targeted delivery of  siRNAs is still  a very
challenging feature or RNAi therapeutics (97).  Although various methods have already
been investigated to deliver siRNA  in vivo (98), it is interesting to note that many cells
produce vesicles displaying tissue-homing properties (99) that could be more than helpful
to deliver therapeutic oligonucleotides in a tissue-specific manner.  It  has already been
shown that small vesicles called exosomes are capable or conveying functional miRNAs
(50). Furthermore, it is possible to modify the tissue-specific homing of these exosomes by
adding viral peptides showing a given tissue-specific tropism, allowing the development of
a broader spectrum of tissue-specific drug delivery vehicles (48).
Exosomes are small lipidic vesicles secreted by many different kinds of cells, and able to
withstand the harsh conditions found in blood circulations. They were first observed during
sheep reticulocyte differentiation, during which the authors have noticed the transfer of
transferrin receptor activity from cells to small vesicles excreted by the cells (100,101).
Despite the absence of a clear consensus on the molecular, biochemical and anatomical
descriptions  of  exosomes,  some  trends  emerge  from  the  many  studies  aiming  at
unraveling the function of exosomes (102-109). According to these studies, exosomes are
60-150 nm large spherical micro-vesicles enriched in various proteins, such as Lamp2b,
Alix, CD63, and displaying various miRNAs such as miR-16-5p for example (110). Many
studies are focused on unraveling the role of exosomes in inter-cellular transfer of nucleic
acids, and more precisely miRNAs (50,111,112). These studies suggest that it might be
possible to transfer small RNA molecules, i.e. therapeutic oligonucleotides, in a tissue-
specific manner by engineering exosomal membrane proteins. However, prior to achieving
this goal, many challenges have to be overcome with respect to exosomes isolation and
characterization, especially given the high level of characterization that any in vivo injected
material must undergo, from both an ethical and from an experimental point of view.
In order to establish protocols for the in vivo delivery of exosomes, it is essential to make
sure that the entities isolated are indeed exosomes. One part of this work therefore aims at
investigating the use of various methods for the characterization of exosomes, including
qPCR-based detection of miRNAs, western-blotting against exosomal proteins, as well as
size measurement by dynamic light-scattering.
Besides the difficulty to demonstrate the presence of exosomes in an absolute manner in a
sample, there is the recurrent concern of determining the best exosomes isolation process.
The second part of this thesis therefore aims at testing a few methods amongst the most
popular isolation processes used in the exosomes field, such as precipitation methods,
differential  ultracentrifugation,  as  well  as  particle  size  separation  methods.  The  ideal
exosomes isolation procedure should consist of as few handling steps as possible, while
generating highly pure exosomes preparations.
B. Characterization of differential ultracentrifugation, the most 
common exosome isolation procedure
B.1. Evaluation of the necessity of a linear sucrose gradient for 
exosomes isolation
Differential ultracentrifugation has been established as a method of choice to isolate pure
exosomes (113).  This  method,  already used for  the fractionation of  cellular organelles
(114), takes advantage of the capability of centrifugation to separate particles according to
their weight and size by the mean of centrifugal forces. This isolation procedure consists in
sequential centrifugation and ultracentrifugation steps aiming at sorting out vesicles from
cell culture supernatant and can be performed with or without sucrose gradient (Fig. 33).
First,  it  is  necessary  to  remove  dead  cells  and  cell  debris  present  in  the  culture
supernatant by subjecting it to low speed centrifugations and discarding the pellet. The
supernatant  is  subsequently subjected to  an ultracentrifugation step at  100,000g for  1
hour, to allow the pelleting of exosomes. After resuspension in a saline buffer like PBS, the
exosomes are ready for characterization or further use. In order to confirm the presence of
exosomes,  this  pelleted  material  can  be  run  on  a  linear  sucrose  gradient  allowing  a
thorough analysis  of  the  exosomal  markers (115).  Most  papers  found in  the literature
therefore  use the  linear  sucrose gradient  only  as  a mean to  confirm the  presence of
exosomes in a sample, such as a study performed by Chen et al (115). In this work, the
author  ran  the  exosome  pellet  on  a  linear  sucrose  gradient  and  shows  presence  of
exosomes in his sample by showing the presence of various exosome markers such as
CD63 or MHC-1 proteins. He then used the previously obtained exosomes pellet for his
subsequent work.
However, the author can not be sure that his exosome sample does not contain any other
contaminating protein. That is why we performed a small study to evaluate whether the
linear sucrose gradient could indeed only be used during exosomes characterization, or
whether  it  would  be  preferential  to  integrate  this  gradient  in  the  exosomes  isolation
procedure.
Figure 33: Differential ultracentrifugation protocols for exosomes isolation. Two protocols were tested, one without linear
sucrose gradient (a) and one with a linear sucrose gradient (b)
We subjected HeLa cell culture supernatant to ultracentrifugation without (Fig. 33a) or with
a linear sucrose gradient step (Fig. 33b). In order to compare both exosomes preparation
methods,  we  selected a parameter  easy to  monitor,  which  is  particle  size,  and which
appears to be a hallmark of exosomes, namely their size, comprised between 50 and 100
nm (116). To monitor the particle size distribution of the exosome preparations we used a
technique called Dynamic Light Scattering (DLS). DLS is a physics technique making use
of the scattering patterns observed when light meets on reflects on small particles. The
integration of these measurements subsequently allows the determination of the size of
the particles present in the analyzed solution (117).
The samples we analyzed consist of cell culture supernatant prior to ultracentrifugation,
resuspended material from a 100,000 g centrifugation step, and the fractions of a linear
sucrose  gradient  performed  on  the  pelleted  material  obtained  after  a  100,000  g
centrifugation step (Fig. 34).
Every sample was measured at least 3 successive times. Non overlapped profiles indicate
an  unstable  solution  or  a  highly  non-homogeneous  solution  most  likely  presenting
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sedimentation or aggregation events, this is why a slight shift can be observed across the
measurements towards the detection of particles displaying on average a larger size.
The particle size determination obtained for an unprocessed medium (Fig. 34a) sample
displayed predominantly particles with a size around 8 to 10 nm, as well as two minor
peaks around 60 to 70 nm, and around 200 nm. This shows that an unprocessed cell
culture  supernatant  contains  a  broad  spectrum  of  particle  sizes  indicating  a  highly
heterogeneous  sample.  Subjecting  this  conditioned  medium  to  a  100,000  g
ultracentrifugation  step  showed  a  shift  of  particle  sizes  towards  bigger  particles,
predominantly around 300 to 500 nm as well as a minor peak around 80 to 100 nm (Fig.
34b). These two particle size distribution patterns indicate that a 100,000 g centrifugation
step results in an enrichment of two groups of particles one of which displays a size range
close  to  the  one  expected  for  exosomes.  However,  these  particles  seemed  to  be  in
minority compared to the other particles displaying larger sizes. This is why we overlaid
this pelleted material on a discontinuous linear sucrose gradient, and determined whether
we could enrich the sample in particles displaying the expected size of 80 to 100 nm (Fig.
34c-j).
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Figure 34: Particle size distribution of samples prepared by ultracentrifugation. Cell culture supernatant was subjected to
DLS measurements prior to any centrifugation (a), or after having undergone a centrifugation step at 100,000 g (b).
Pelleted material was subsequently overlaid on a linear sucrose gradient, and the fractions of the gradient were
subjected to DLS measurements (c-j). The samples are shown according to the fraction of the sucrose gradient they
were in, going from 35% sucrose (c) to 70% sucrose (j)
The correct establishment of the gradient could be monitored by the disappearance of the
interphases located between each of the overlaid sucrose fractions. The particles present
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in the 70% sucrose fraction (Fig. 34j) displayed a size around 600 to 700 nm, whereas the
particles  isolated  from other  fractions  of  the  linear  sucrose  gradient  displayed  a  size
around 200 nm, independent of the sucrose content (Fig. 34c-i). Although exosomes are
expected to display a density allowing them to be enriched in fractions containing 40 to
60% sucrose (118), there was no correlation between sucrose concentration and particle
size in this study. However, the fact that we could see a selective enrichment in particles
displaying  a size around 200 nm, as well  as the fact  that the particle size distribution
profiles indicated homogeneous samples because of the overlapping profiles, prompted us
to conclude that an efficient exosomes isolation process can only benefit from the addition
of a linear sucrose gradient. This linear sucrose gradient should however not be used only
for  exosomes  characterization  as  it  can  be  seen  in  some  studies,  but  rather  as  an
essential preparative step.
As to the use of dynamic light scattering as an exosomes quality control, the fact that the
particle size distribution did not change as a function of sucrose concentration led us to
hypothesize that particle size determination was not an ideal characterization method for
exosomes and could not be used on its own as an efficient way to assess the presence of
exosomes in a given sample.
B.2. Molecular biological characterization of exosomes by triton-
dependent detection of miRNAs and siRNAs
A.1.a) Triton-dependent detection of miR-16-5p in exosome 
samples
The accumulation of evidences showing the presence of various mRNAs and miRNAs in
exosomes and the role of exosomes in inter-cellular communication via transfer of RNAs
prompted us to develop an assay based on the RT-qPCR detection of exosomal RNAs
(111,119,120).
Since  a  common  method  used  to  investigate  the  encapsulation  of  siRNAs  in  Lipid
Nanoparticles (LNP) consists in a Triton-dependent siRNA detection (121), we applied our
in-house developed miRNA RT-qPCR method to exosome samples subjected or not to
Triton-mediated  solubilization.  The  detection  of  miRNAs  in  Triton-treated  exosomes
samples  vs.  untreated  exosomes  samples  should  therefore  allow  us  to  assess  the
presence of exosomal miRNAs in a sample.
According  to  a  study  by  Gibbings  et  al  (122),  the  major  constituent  of  the  exosomal
miRNome is miR-16-5p. We therefore designed RT-qPCR primers against miR-16-5p and
used Triton-X-100 to release the exosomal content, and thus make it available for RT-
qPCR-based  detection.  Exosomes  were  prepared  by  differential  ultracentrifugation
followed by a linear sucrose gradient step (Fig. 33b on page 49).
In  order  to  benchmark the Triton-X-100 dependent  detection of  miR-16-5p,  we  diluted
fractions from the sucrose gradient 1:2 in either TCEP Lysis Buffer containing Triton-X-100
or PBS as a negative control,  since PBS should not be able to release the exosomal
content.  The samples were subsequently diluted 1:5 or 1:10 in DEPC-treated water  to
avoid buffer-mediated inhibition of the RT-qPCR reaction (Fig. 35).
Figure 35: Triton-X-100 dependent miR-16-5p quantification by RT-qPCR. Bar graph showing the miR-16-5p quantities
detected in each fraction of the sucrose gradient, treated either with PBS (grey) or with Triton and diluted 1:5 (dark blue)
or 1:10 (light blue) in DEPC water
Only  the  samples  treated  with  TCEP  Lysis  Buffer  supplemented  with  Triton-X-100
displayed detectable amounts of miR-16, whereas signals obtained for the PBS-treated
samples were non-detectable.
An average 2-fold difference in miR-16 levels observed between the 1:5 and 1:10 diluted
lysed exosomes indicated that  the PCR amplification did not  suffer  from the inhibitory
elements present in the lysis buffer. In all following experiments the lysates were diluted
1:10 in DEPC water prior to RT-qPCR measurements.
Unfortunately this profile was not completely satisfactory, since exosomes are supposed to
be  contained  in  the  fractions  containing  40  to  60%  sucrose  (118).  Although  a  slight
increase  in  miR-16  signals  could  be  observed  in  the  fractions  containing  40  to  70%
sucrose, this observation did not appear to be significant, since the levels were barely
higher in these fractions than the ones detected in the 10 to 35% sucrose fractions.
As a next step, we also tested the possibility to detect a less abundant exosomal miRNA,
namely miR-191-5p, in a Triton-dependent manner (122). Unfortunately, we were unable
to detect miR-191-5p in any of these samples. This can be explained by the fact that the
amount of exosomes recovered by differential ultracentrifugation was too low to allow the
detection of a low abundant miRNA. The low amounts of exosomes in the samples could
also be confirmed by the fact that the highly abundant exosomal miRNA miR-16-5p could
only by detected in limited amounts.
To  confirm this  hypothesis  we  repeated  this  experiment  by  increasing  the  amount  of
starting  material,  in  our  case  HeLa  cell  culture  supernatant,  subjected  to  differential
ultracentrifugation (Fig. 36).
Figure 36: Triton-dependent detection of miR-16-5p in fractions of a sucrose gradient used for exosomes preparation
The profile obtained for the quantification of miR-16-5p in figure 36 shows an increase in
signals  in  fractions  containing  40  to  60% sucrose,  precisely  the  fractions  reported  to
contain exosomes (118). Moreover the signals measured in these fractions are Triton-X-
100 sensitive, since the same fractions treated with PBS did not display any signal. An
interesting fraction though is the fraction containing 70% sucrose, located at the bottom of
the  tube  during  the  ultracentrifugation  step  allowing  the  establishment  of  the  sucrose
gradient. The fact that this fraction displays such a high miR-16 level may be explained by
either the presence of smaller vesicles containing miR-16 not floating at the same density
as exosomes, or by the existence of a Triton-sensitive protein complex containing miR-16.
Taken together  these data  suggest  that  it  is  possible  to  isolate Triton  X-100-sensitive
entities  containing  miR-16-5p  by  subjecting  cell  culture  medium  to  differential
ultracentrifugation  followed  by  a  linear  sucrose  gradient.  Further  characterization  was
required to confirm the presence of exosomes in the fractions of the sucrose gradient.
A.1.b) Triton-dependent detection of a YFP siRNA encapsulated 
in exosomes
The capability to detect an endogenous miRNA encapsulated in exosomes in a Triton-
sensitive manner prompted us to pursue the detection of exogenous oligonucleotides in
exosomes. We therefore tested the capability of cells to pack a siRNA into exosomes by
transforming HeLa cells with a plasmid encoding a shRNA targeting YFP. The YFP shRNA
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was selected in  order  to  perform exosomes transfer  experiments in  a YFP-expressing
HeLa cell line we had at our disposal.
After  their  transformation,  we  subjected  HeLa  cells  conditioned  medium to  exosomes
isolation by differential  ultracentrifugation,  and quantified both miR-16-5p and the YFP
siRNA by Triton-sensitive RT-qPCR (Fig. 37).
Figure 37: Triton-dependent detection of miR-16-5p and YFP siRNA in fractions of a sucrose gradient used for
exosomes preparation
Both miR-16-5p and the YFP siRNA could be detected in a Triton-sensitive manner in
fractions  from  the  linear  sucrose  gradient.  Both  targets  could  be  detected  in  higher
amounts in the fraction containing 55, 60 and 65%. In the case of the YFP siRNA however,
the amounts obtained were lower than the ones obtained for miR-16-5p, but since they
vary by only 2-fold, this difference could be due to the error range of the PCR reaction.
Performing this  experiment  suggested that  it  was  possible  to  encapsulate  a siRNA in
exosomes by transforming a cell line with the according shRNA.
Transwell assays aiming at showing the transfer of this YFP siRNA to a recipient YFP-
expressing HeLa cell line via exosomes unfortunately did not show any variations in the
expression level of the YFP mRNA in the recipient cell line. This might suggest that even
encapsulation of an siRNA in exosomes is possible, delivery of the siRNA via exosomes
might be not efficient enough to promote the knock-down of an mRNA, or that the siRNA
amounts present in these exosomes were too low to enable efficient knock-down of the
target mRNA.
B.3. Proteomic characterization of exosomes by detection of 
exosomal proteins
In the previous section we discussed the possibility to use the exosomal miRNome as an
indication of the presence of exosomes. Even though we could detect miR-16-5p in a
Triton-dependent manner,  this only shows that  we isolated a detergent-sensitive entity
containing miR-16-5p. In order to make sure that we indeed isolated exosomes, we had to
show  that  the  fractions  displaying  high  miR-16-5p  levels  also  showed  presence  of
exosomal protein markers. In order to select an exosomal protein marker we used the
ExoCarta database, which offers a compilation of every RNAs and proteins reported to be
present in exosomes (110). Although several surface proteins are described as “exosomes
markers”, we decided to use a protein located in the exosomes, or a protein known to
interact  with  a protein  known to  be present  in the exosomes.  This  way,  we hoped to
decrease the risk of false positives that could occur by using a surface protein which could
otherwise  be  present  on  a  variety  of  cellular  vesicles.  During  our  investigations  we
identified  the  Endosomal  Sorting  Complex  Required  for  Transport  (ESCRT)  as  a  key
player in the selection of exosomes content (123,124). However this protein complex is
located on the membrane of Multivesicular Bodies (MVB), and is most of the time not
included  in  exosomes.  Therefore  we  investigated  the  use  of  an  ESCRT  associated
proteins, namely the Programmed Cell Death 6 Interacting Protein (PDCD6IP), also known
as Alix,  as an exosomal marker (125-127). Interestingly this protein is one of the most
used exosomal markers in the studies listed in the ExoCarta, further validating our idea to
use Alix as exosomal marker.
In order to better correlate our previous observations with respect to miR-16-5p Triton-
dependent detection with the presence of exosomes, we subjected cell culture supernatant
to differential ultracentrifugation. The fractions of the sucrose gradient were subsequently
analyzed  by RT-qPCR,  as  described previously,  and by  western-blot  to  check for  the
presence of Alix.  The differential  ultracentrifugation protocol was performed on the cell
culture medium obtained from two different cell lines, namely HeLa cells and MS1 cells,
previously shown to secrete exosomes (unpublished data, Bonenfant et al).
While  the  HeLa  cell  culture  supernatant  was  used  only  to  benchmark  the  exosome
characterization methods, the use of MS1 cell culture supernatant was motivated by the
possibility to perform mouse in vivo studies, requiring the use of exosomes of murine origin
to minimize immune responses induced by exosomes (128).
A.1.a) Characterization of exosomes isolated from HeLa cell 
culture medium
We followed the same procedure as the one already described in the previous section,
namely that we tested the Triton-dependent quantification of miR-16-5p in each fraction of
the sucrose gradient and we subsequently performed a western-blot  using an anti-Alix
antibody on the same fractions (Fig. 38). The miR-16 profile obtained in this experiment is
showing  increased  miR-16  levels  in  the  fractions  containing  45  and  60%  sucrose
compared to the other fractions (Fig. 38, upper panel). However, in these two fractions
we also observed relatively high miR-16 levels when the sample was treated with PBS.
This indicates a high level of non-encapsulated miR-16-5p, suggesting either the existence
of a subpopulation of miR-16-5p molecules which are not associated with exosomes, or
that sample handling during differential ultracentrifugation procedure mechanically disrupts
exosomes, and therefore releases miR-16-5p.
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Figure 38: Correlation between miR-16 positive signals and Alix protein detection by Western-blot in HeLa cell culture
supernatant. Triton-sensitive quantification of miR-16-5p (upper panel) and western blot with an Anti-Alix antibody (lower
panel)
Western blot analysis against Alix (Fig. 38, lower panel) correlated with miR-16 positive
sucrose gradient fractions, namely in the fractions containing 45 and 60% sucrose, but in a
lesser extent in the fractions containing 40 and 70% sucrose. After a closer examination of
the miR-16 quantification results, we noticed that high levels of miR-16 are not enough to
show the presence of exosomes, but that the signal difference between PBS- and Triton-
treated samples is a better indicator of the presence of exosomes in a given sample.
In  summary  this  data  seems  to  indicate  presence  of  exosomes  given  the  observed
correlation between triton-dependent miR-16 detection and western blot results obtained
for Alix.
A.1.b) Characterization of exosomes isolated from MS1 cell 
culture medium
The miR-16-5p profile  obtained in  exosomes samples prepared from MS1 cell  culture
medium is a perfect example of what is expected from such an experiment, namely that
miR-16 levels should display a gauss curve-like distribution centered on 40-50% sucrose,
and that signals obtained for PBS-treated samples should remain relatively low (Fig. 39,
upper panel).
Moreover, as it could be shown in the previous experiment, a western blot performed on
these samples targeting Alix showed signals in the fractions which were shown to be miR-
16 positive (Fig. 39, lower panel), thereby confirming the presence of exosomes in these
fractions of the sucrose gradient.
Figure 39: Triton-sensitive quantification of miR-16 in fractions of a sucrose gradient performed using MS1 cell culture
supernatant (upper panel) and western blot using an Anti-Alix antibody (lower panel)
As  a  conclusion,  we  could  successfully  show  the  possibility  to  use  Triton-dependent
detection of miR-16-5p as an assay to demonstrate presence of exosomes in a given
sample,  since  only  the  miR-16  positive  samples  did  show  detectable  and  significant
amounts  of  Alix  protein.  The  other  advantage  of  RT-qPCR  over  western-blot  for  the
characterization of exosomes preparations is the higher speed and less handling steps
required for sample analysis. RT-qPCR is however not a perfect tool either, since a high
amount of the isolated material is required for this analysis step. Samples characterization
using non-invasive methods such as DLS could also not be used on their own, because of
the  low amount  of  information  they  provide.  A  good  compromise  could  reside  in  the
combination  of  particle  size  determination  and  Triton-dependent  detection  of  miRNAs
abundant in exosomes, since this would give us the possibility to monitor two important
characteristics of the exosomes.
Although the exosomes analytics has been established, the exosomes isolation procedure
based  on  differential  ultracentrifugation  is  still  questionable.  Among  the  various
experiments performed with this technique it was almost impossible to obtain twice the
same  miR-16-5p  detection  profile,  indicating  the  low  reproducibility  of  this  technique.
Moreover the detection of miR-16-5p in samples which were not treated with Triton-X-100
tends to  suggest  that  this  isolation  procedure  damages the  exosomes to  the  point  of
releasing their content because of the intermediate handling steps and high centrifugal
forces.  Moreover,  since the  aim of  these studies is  to  generate  exosomes for  in  vivo
applications,  and  since  this  protocol  requires  a  high  hands-on  level,  it  would  be  a
challenge to adapt this method to the sterile and highly controlled conditions required for in
vivo experimentation. Furthermore, this protocol displays a rather elevated batch-to-batch
variation level, unsuited to comparative in vivo studies. It is therefore crucial to identify a
highly  reproducible  and  sterile  exosomes  isolation  method,  other  than  differential
ultracentrifugation.
C. Use of particle size-based isolation methods for exosomes 
isolation
Methods  allowing  the  purification  of  liposomes in  sterile  conditions  to  perform  in  vivo
silencing  studies  using  LNP-siRNA  complexes  offer  characteristics  that  could  be
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applicable to exosomes isolation. Tangential Flow Filtration (TFF) for instance, frequently
used for the purification of LNP-encapsulated siRNAs (129), could be used for exosomes
isolation.
In this section, we therefore tested TFF as well as ultrafiltration, another method based on
particle size separation, taking advantage of the characteristic size of exosomes.
C.1. Exosomes isolation by ultrafiltration
In order to test the potential of ultrafiltration we tested two different ultrafiltration devices
from  Pall,  one  with  a  100  kDa  cut-off  membrane,  and  one  with  a  300  kDa  cut-off
membrane. Both devices were tested on cell culture supernatant from two different cell
lines, HeLa cell line and a human monocyte derived dendritic cell line. The advantage of
these devices is the possibility to select and enrich a sample in particles of a given size,
but  also  to  use  far  lower  centrifugal  forces  than  the  ones  required  in  differential
ultracentrifugation procedures. Briefly, these devices are composed of two compartments
separated by a membrane characterized by its pore size and the molecular weight of the
molecules  it  will  be  able  to  retain.  The  solution  to  process  is  added  to  the  top
compartment,  onto  the  membrane,  and  the  device  is  subsequently  submitted  to
centrifugation at maximum 3,000 g. The liquid will  end up in the bottom compartment,
containing all particles smaller than the molecular weight cut-off of the membrane and is
called  the  flow-through.  All  particles  bigger  than  the  molecular  weight  cut-off  of  the
membrane will on the other hand be retained by the membrane, and this solution will be
called  the  retentate.  The  flow-throughs  and  retentates  were  subjected  to  exosomes
analytics by particle size determination and Triton-dependent miR-16-5p detection.
A.1.c) Ultrafiltration of HeLa cell culture medium
The cell culture supernatant was subjected to ultrafiltration according to the manufacturer’s
recommendations,  using  two  different  molecular  weight  cut-offs.  In  both  cases  the
retentate as well as the two flow-throughs were analyzed by Dynamic Light Scattering and
tested for their miR-16 content (Fig. 40 and 41).
All  the  samples  were  subjected  to  Triton-dependent  miR-16  detection  by  RT-qPCR;
however  despite  the  good  sensitivity  obtained,  no  miR-16  could  be  detected  in  any
samples.
The DLS profile of  the samples isolated on the 100 kDa cut-off  membrane (Fig.  40a)
interestingly indicated 2 major peaks, centered on 8 and 55 nm as well as a minor peak
centered on 300 nm. The flow-throughs (Fig. 40b-c) displayed major peaks at 0.8, 8 and
300 nm, confirming the retention of particles with a size around 55 nm.
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Figure 40: Dynamic Light Scattering profiles obtained by purifying HeLa cell culture supernatant with a 100 kDa cut-off
ultrafiltration device. a: particle sizes profile of the retentate. b-c: particle sizes profile of the two flow-throughs
The  results  obtained  for  samples  isolated  on  the  300  kDa  cut-off  membrane  were
surprisingly similar, although we could notice the presence of only two major peaks in the
retentate fraction (Fig. 41a) centered on 8 and 60 nm. In this experiment the flow-throughs
(Fig.  41b-c)  showed  as  well  peaks  centered  on  0.8  and  8  nm  confirming  again  the
retention of 55-60 nm large particles on the membrane.
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Figure 41: Dynamic Light Scattering profiles obtained by purifying HeLa cell culture supernatant with a 300 kDa cut-off
ultrafiltration device. a: particle sizes profile of the retentate. b-c: particle sizes profile of the two flow-throughs
Taken together, these data indicate the possibility to select particles based on their size in
quite a robust fashion. However, since we failed to detect miR-16-5p it is difficult to confirm
that the isolated particles were indeed exosomes.
In  the  previous DLS measurements  involving  particles  isolated  from HeLa cell  culture
supernatant by differential ultracentrifugation, the average size of the particles was around
200 nm. By using ultrafiltration, we isolated 4-fold smaller vesicles, so this could suggest
that an event of aggregation or vesicles fusion might occur during ultracentrifugation, thus
artificially generating bigger vesicles.
Although  it  is  reported  that  HeLa  cells  also  secrete  exosomes  (130),  the  amount  of
exosomes secreted by HeLa cells could be insufficient to perform extensive work using
exosomes generated using this cell line. We therefore tested cell culture supernatant from
human  monocyte  derived  dendritic  cells,  a  cell  line  which  was  more  extensively
investigated in the exosomes field than HeLa cells, and which supposedly secrete higher
amounts of exosomes (131-133).
A.1.d) Ultrafiltration of monocyte derived dendritic cells (MODC) 
cell culture supernatant
The cell culture supernatant was subject to the same analysis than the HeLa cell culture
supernatant and the results obtained are shown in the figures 42 and 43.
As in the previous experiment, no miR-16-5p could be detected in these samples, although
miR-16-5 is expressed in these cells (134). The fact that we failed to detect miR-16-5p in
the processed samples suggests that the exosomes amount might have been too low to
allow detection of this miRNA.
The very first observation that can be made is the very low variability observed between
the various measurements indicating a very homogenous sample preparation and stable
solutions over time (Fig. 42a and 43a). Only two major peaks could be observed at 8 and
90-100 nm (Fig. 42a), whereas the flow-through displayed peaks at 8 and 50 nm and a
very broad peak indicating the presence of particles with a size comprised between 200
and 5,000 nm (Fig. 42b), thereby confirming the retention of 90-100 nm large particles.
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Figure 42: Dynamic Light Scattering profiles obtained by purifying MODC cell culture supernatant with a 100 kDa cut-off
ultrafiltration device. a: particle sizes profile of the retentate. b: particle sizes profile of the flow-through
The results  obtained with  the 300 kDa cut-off  membrane were  almost  identical  to  the
results obtained with the 100 kDa membrane. We indeed observed two major peaks at 8
and 90-100 nm in the retentate (Fig. 43a), whereas the flow-through displayed peaks at
0.8, 8 and 200 nm (Fig. 43b).
The presence of the 8 nm peak in all the analyzed samples might suggest the presence of
protein aggregates or fractionated vesicles both in the retentates and in the flow-throughs.
It is highly probable that these 8 nm particles were artificially generated by the centrifugal
force applied on the vesicles which forced them to pass through the pores of the various
membranes tested thereby fractionating them.
As a conclusion, although the centrifugal forces applied on the exosomes in such devices
is significantly lower than the ones applied in differential ultracentrifugation protocols, there
is still the danger to artificially generate fusion of particles in the retentate fraction and to
damage particles located directly on the membranes.
Furthermore, the fact that we failed to detect miR-16-5p in any of the previously analyzed
samples  did  not  prove  that  the  entities  isolated  were  indeed  exosomes,  therefore
invalidating  even  more  the  use  of  such  ultrafiltration  devices  for  the  preparation  of
exosomes for in vivo applications.
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Figure 43: Dynamic Light Scattering profiles obtained by purifying MODC cell culture supernatant with a 300 kDa cut-off
ultrafiltration device. a: particle sizes profile of the retentate. b: particle sizes profile of the flow-through
C.2. Exosomes isolation via Tangential Flow Filtration, a method used
for Lipidic Nanoparticles purification
The TFF method is based on the continuous circulation of a solution on a filtration cassette
allowing the retention of particles of a given size (135). The particle size is defined by the
pore size of the filtration cassette, and pressure applied on the cassette allows particle-
free liquid to pass through the membrane, resulting in a reduction of circulating fluid (Fig.
44). 
Figure 44: Tangential Flow Filtration procedure. (1) Sample reservoir, containing the retentate (2) Peristaltic pump (3)
Feed pressure gauge (4) TFF cassette (5) Transmembrane pressure gauge (6) Screw clamp valve (7) Filtrate collector
This  mechanism  is  used  to  concentrate  particles  and  to  possibly  eliminate  non-
encapsulated material (136). The solution still present in the system after processing and
which contains the particles of the desired size is called the retentate, while the solution
passing through the membrane is called the filtrate. In our case, TFF will be used as a
mean to concentrate cell culture supernatant, and to select ideally particles with a size
around 60 to 100 nm, namely the size range of exosomes.
We therefore subjected 500 mL HeLa cell culture supernatant to TFF and analyzed the
retentate both by Triton-dependent  miR-16 detection by RT-qPCR and to particle  size
measurement by DLS (Fig. 45).
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Figure 45: Dynamic Light Scattering profiles obtained by purifying HeLa cell culture supernatant with a 100 kDa cut-off
TFF device. a: particle sizes profile of the conditioned medium. b: particle sizes profile of the TFF retentate
The particle size profile obtained for a sample which did not undergo TFF purification
(annotated as crude) show a major peak at 8 nm, as well as minor peaks at 60 nm and
5,000 nm (Fig. 45a), whereas the TFF-purified material showed major peaks at 8, 40 and
200-500 nm (Fig. 45b). This dataset might therefore suggest an enrichment of particles
with  a  size  around  40  nm  after  TFF  purification.  Surprisingly,  the  three  consecutive
measurements  were  not  perfectly  overlaid  indicating  a  highly  heterogeneous  solution
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suggesting that although it is in theory possible to select a minimal particle size, it is very
difficult to select a specific size range.
Furthermore, despite an enrichment in particles with a size around 40 nm, no miR-16-5p
could be detected in any of the tested samples making it difficult to conclude whether the
samples indeed contained exosomes. Another possibility  could be the presence of too
many  PCR  inhibitory  compounds  from  serum  in  the  retentate  since  it  was  highly
concentrated.  We therefore decided to  run the retentate on a linear  sucrose gradient,
hoping to reduce the amount of  inhibitory compounds in the samples and to therefore
allow Triton-dependent miR-16-5p detection by RT-qPCR (Fig. 46).
Figure 46: Triton-dependent miR-16-5p quantification in TFF retentate purified on a linear sucrose gradient
The crude sample, which did not undergo TFF purification, as well as the fractions of the
sucrose gradient, were subjected to Triton-dependent miR-16-5p detection by RT-qPCR.
Although the 60 and 65% sucrose fractions show higher amounts of miR-16-5p compared
to other fractions, the fraction containing 70% of sucrose displayed even higher levels of
miR-16-5p compared to the 60 and 65 % sucrose fractions, suggesting again loss of miR-
16 encapsulation due to damages caused to the exosomes by the handling procedure.
Very  much to  our  surprise,  the  miR-16-5p levels  detected in  the  crude,  unprocessed,
sample were close to the amounts detected in the 60 and 65% sucrose fractions, although
we were expecting a significant enrichment of the miR-16 amounts since we were able to
concentrate 500 mL cell culture supernatant down to 15 mL retentate. This might suggest
that a significant amount of miR-16-5p is not encapsulated in exosomes and might rather
be involved in a complex or bound to an entity smaller than 100 kDa, allowing it to pass
through the membrane pores and to therefore be less abundant than expected in  the
retentate.
As a summary, the isolation of exosomes based on particle size separation seems to be
not  as  efficient  as  expected,  since  we  could  not  detect  miR-16-5p  in  a  Triton-X-100
sensitive manner, suggesting that either exosomes were present in too low amounts in the
sample,  or  that  there  were  no  exosomes  at  all  in  our  sample.  Moreover,  the
heterogeneous  particle  size  distributions  obtained  indicated  the  possible  presence  of
various  unidentified  particles  or  protein  complex,  making  the  use  of  these  samples
impossible in in vivo studies.
D. Isolation of exosomes by polymers-driven precipitation
D.1. Evaluation of a commercially available exosomes isolation kit, 
ExoQuick
A  few  years  ago,  the  company  System  Biosciences  commercialized  an  exosome
precipitation solution called ExoQuick (137). ExoQuick is a polymer-based reagent created
to enrich a sample, i.e. cell culture supernatant, blood, urine, in exosomes. Moreover the
very few steps required in this isolation protocol make it quite eligible for the establishment
of a sterile and controlled preparation procedure for in vivo studies. This isolation method
relies on a single overnight incubation step at 4°C followed by a centrifugation step at
3,000  g,  enabling  the  precipitation  of  exosomes.  The  ExoQuick  isolation  method was
tested on cell  culture supernatant and the pelleted material  was subjected to a Triton-
dependent miR-16-5p detection (Fig. 47).
Figure 47: Triton-dependent quantification of miR-16 in ExoQuick isolated material. Values are averages of 3
measurements. Error bars, STDEV (n=3)
The precipitation of 15 mL HeLa cell culture supernatant using ExoQuick allowed us to
detect a small amount of Triton X-100 dependent miR-16-5p, but given the size of the error
bars  obtained,  the  data  did  not  allow to  draw conclusions  on  the  exosomes isolation
procedure using ExoQuick. None of the similar experiments performed using ExoQuick-
based isolation did result in a better miR-16-5p detection profile, showing the poor efficacy
of this isolation kit, at least in our hands. However, when considering that the polymers
constituting this kit are unknown, we invalidated its use to prepare exosomes for  in vivo
studies, since it would be unethical to inject an unknown compound in vivo. Moreover, the
constituents  of  this  solution  might  interfere  with  subsequent  transfection  or  transfer
experiments  involving  exosomes,  and  therefore  rendering  these  experiments  non-
interpretable.
D.2. Evaluation of a virus particle isolation method, Polybrene/CSC 
precipitation
Since growing evidence suggests that exosomes and enveloped virus such as HIV are
generated by the same secretory mechanisms in the multi-vesicular bodies (MVB) (138-
141), we explored the use of virus particle isolation methods for exosomes purification.
Taking advantage of the structural similarities between enveloped virus and exosomes,
such as negatively charged membranes and the presence of transmembrane proteins on
their  surface,  should  allow  us  to  investigate  the  use  of  a  virus  isolation  method  for
exosomes isolation. This precipitation method is based on the complexation of negatively
charged  particles  with  the  positively  charged  polymer  polybrene,  and  the  negatively
charged  polysaccharide  Chondroitin  Sulfate  C  (CSC)  (142).  These  complexes  are
subsequently centrifuged at low speeds involving not more than 3,000 g. This method is
later referred to as Polybrene/CSC precipitation (Fig. 48a).
However,  since the fate of the exosomes we isolate is to be injected  in vivo to trigger
targeted delivery of therapeutic siRNAs, it is crucial for our exosomes preparations to not
contain  any  moiety  other  than  exosomes.  The  presence  of  the  polymers  used  for
precipitation can therefore not  be tolerated in the samples.  By using a polymer  which
charges can be modified  by  pH variations,  we  could  initiate  the  disassembling  of  the
exosomes-polymers complex and therefore release the exosomes in solution (143). This is
possible by using polyethylenimine, which is protonated, and therefore positively charged
at  low pH, whereas at  a  pH superior  to  its  pKa,  this  polymer  becomes neutral  (144),
therefore disrupting the polymers-exosomes complexes (Fig. 46b). 
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Fig. 48: Mechanism of Polybrene/CSC (a) and PEI/CSC (b) precipitation methods
Prior  to  any  work  with  the  pH-labile  PEI,  we  tested  the  possibility  to  use  the
polybrene/CSC  precipitation  method  for  the  isolation  of  exosomes  out  of  cell  culture
supernatant.
A.1.e) Titration of the reagents for optimal polybrene/CSC 
precipitation for exosomes isolation
This experiment aimed at determining the optimal amounts of both polymers that have to
be used for an optimal recovery of exosomes, which presence was assessed by both miR-
16-5p quantification by RT-qPCR and western blotting (Fig. 49).
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Figure 49: Characterization of the Polybrene/CSC material by RT-qPCR and Western Blotting. upper panel: miR-16-5p
levels in Polybrene/CSC precipitated material. The x-axis indicates the concentration of CSC in μg/mL. lower panel:
western blot analysis using an anti-CD63 antibody
The first characterization of this precipitation method consisted in determining the optimal
ratio between both polymers. To achieve this, we subjected HeLa cell culture supernatant
to Polybrene/CSC precipitation by keeping the Polybrene constant, at 500 µg/mL and by
increasing the CSC concentration from 0 to 5,000 µg/mL. Every sample was then split in
two  fractions,  one  for  western  blotting  (Fig.  49,  lower  panel)  and  one  for  total  RNA
extraction with Trizol (Fig. 49, upper panel). Unfortunately we could not detect any Alix
protein by western-blotting, and we therefore selected another exosomal marker, namely
the tetraspanin protein CD63 (110).
The quantification of miR-16-5p,  showed an interesting dose response effect  (Fig.  49,
upper panel). There is indeed an increase in miR-16 levels along with the increase in
CSC  concentration  used  in  the  precipitation.  Surprisingly,  this  correlation  was  only
observed up to a CSC concentration of 1,000 μg/mL, although the CD63 western blot (Fig.
49, lower panel) displayed increasing signals along with increasing CSC concentration up
to 5,000 μg/mL.
We therefore decided to use 1,000 μg/mL CSC in the following experiments, since the
correlation between CSC concentration, CD63 and miR-16 signals was only observed up
to this specific concentration.
A.1.f) Co-precipitation of miR-16-5p and Ago2 in polybrene/CSC 
precipitated material
We subsequently intended to  prepare samples for  more extensive proteomics studies,
aiming at confirming the presence of exosomes specific proteins in the samples isolated
by Polybrene/CSC precipitation, using Liquid Chromatography Mass Spectrometry (LC-
MS).  The  samples  used  in  this  study  were  assessed  for  the  presence  of  exosomes
markers prior to any further analysis (Fig. 50).
Figure 50: Characterization of Polybrene/CSC precipitated material by RT-qPCR and western blot. upper panel: miR-
16-5p levels in Polybrene/CSC precipitated material. The x-axis indicates the sample tested: HeLa or 3T3 cell culture
supernatant, DMEM Medium supplemented with 10% FCS, or DMEM Medium without serum. middle panel: western
blot analysis using an anti-CD63 antibody. lower panel: western blot analysis using an anti-Ago2 antibody
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The cell culture supernatant of two different cell lines were analyzed, HeLa cells since all
previous work had been performed on this cell line, and 3T3 cells, since cell culture of this
cell line had already been subjected to LC-MS by Debora Bonenfant and could therefore
be used as a reference. We furthermore complemented the sample set with two negative
controls, namely non-conditioned cell culture medium supplemented or not with Fetal Calf
Serum (FCS).
The miR-16 amounts detected in the HeLa cells conditioned medium were higher than the
miR-16 levels  detected in  any of  the  other  samples  (Fig.  50,  upper  panel),  possibly
indicating  the  presence of  exosomes in  the  sample.  The 3T3 cell  culture  supernatant
however,  did  not  contain  more  miR-16-5p  than  non-conditioned  medium.  We  could
therefore not conclude on the presence or the absence of exosomes in this conditioned
medium.
The presence of exosomes had therefore to be confirmed by western blotting against an
exosomal marker, namely CD63 (Fig. 50, middle panel).
The  CD63  antibody  surprisingly  generated  signal  in  all  samples,  although  we  only
expected CD63-positive signals in miR-16-positive samples (Fig. 50, middle panel).
The fact that non-conditioned medium containing no serum displayed signal suggested
that either the CD63 or secondary antibody was non-specifically binding to a reagent used
in  polybrene/CSC precipitation.  A more  thorough analysis  of  the  western  blots  results
obtained in  the previous experiment  (Fig.  49)  suggested that  this  non-specific  binding
increased over  titration of  the CSC in  the  precipitation mix,  indicating  that  one of  the
antibodies might non-specifically bind to CSC, therefore we could see positive signals in
non-conditioned medium using the CD63 antibody (Fig. 50, middle panel). 
The non-specific binding of the CD63 antibody to the polymers however does not explain
why  we  could  detect  miR-16-5p  in  the  HeLa  cells  conditioned  culture  supernatant.
Surprisingly,  it  was  reported  at  the  same  time  that  miRNAs  circulating  in  blood,  i.e.
excreted miRNAs, might not only be encapsulated in exosomes, but could also be found in
complex with proteins such as Ago2 for example (145,146). We therefore investigated the
presence of Ago2 by western blot in the previously analyzed samples and compared the
miR-16-5p and the Ago2 levels (Fig. 50, lower panel). Only the miR-16-positive HeLa cell
culture supernatant displayed substantial Ago2 signals, indicating co-precipitation of the
Ago2 protein along with miR-16-5p.
Intrigued by the co-precipitation of both the Ago2 protein and miR-16-5p, we subjected
HeLa  cell  lysate  to  Polybrene/CSC  precipitation  in  order  to  better  understand  the
mechanisms which could have led to this observed co-precipitation.
A.1.g) Identification of RNA- and DNA interacting proteins in 
Polybrene/CSC precipitated cell lysate
A list of 1042 peptides could be identified in polybrene/CSC precipitated HeLa cell lysate
(see Appendix II). The analysis of their function resulted in the striking observation that a
little  less  than  60% of  these  peptides  were  originating  from DNA-  or  RNA-interacting
proteins (Fig. 51, dark orange).
Figure 51: Classification of the identified peptides as DNA/RNA interacting proteins (dark orange) or non-DNA/RNA
interacting proteins (light orange)
Although a vast majority of the DNA/RNA-interacting proteins identified in this sample were
ribosomal proteins, subunits of the translation initiation factors 2 and 3 could also be found
in this sample. The high proportion of these proteins, involved in mRNA translation, in the
precipitated material suggests that either the polybrene/CSC precipitation is able to pull
down a certain type of proteins, or that the conditions used for polybrene/CSC precipitation
allow the complexes formed between mRNA, rRNA and the translational machinery to
remain  intact.  This  second  hypothesis  therefore  suggests  that  the  polybrene/CSC
precipitation is able to precipitate negatively charged material, such as RNA, and that the
proteins in complex with this RNA are being pulled-down along with the precipitated RNA.
Further analysis  of  the precipitated proteins revealed the presence of several  types of
DNA-interacting proteins, such as histones, transcription factors, nucleolar proteins, RNA
Polymerase  II  interacting  proteins,  suggesting,  as  for  proteins  involved  in  mRNA
translation, that these protein complexes are kept intact throughout precipitation, and that
Polybrene and CSC interact with negatively charged polymers such as RNA and DNA.
Interestingly, not only could nuclear and cytoplasmic RNA- and DNA-interacting proteins
be identified, but also mitochondrial proteins involved in DNA and RNA interactions, such
as mitochondrial  ribosomal  proteins,  mitochondrial  translation  and transcription factors.
This observation suggests that  although the lysis  conditions used prior  to  precipitation
allowed the release of cytoplasmic, but also nuclear and mitochondrial material in solution,
nucleoproteic complexes remained intact, allowing their pull-down via negatively charged
nucleic acid molecules.
This  observation  raised  many  hopes  for  potential  applications  of  the  Polybrene/CSC
precipitation method, such as for example identifying the actors of miRNAs circulation in
blood, the proteins allowing their delivery to specific tissues, assuming there would be a
cell-to-cell transfer of miRNAs-containing protein complexes.
LC-MS  experiments  aiming  at  identifying  proteins  isolated  from  mouse  plasma  with
Polybrene/CSC however  did  not  allow the  identification  of  many DNA/RNA interacting
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proteins, apart from Ago2, and translation factors known to be present in blood. The vast
majority of the identified proteins were part of the immune system and of the complement.
When trying to perform similar studies in human plasma, we unfortunately failed to detect
any miRNAs, leading to the halt of the project.
B. Conclusion/Discussion
The  data  presented  here  illustrates  the  challenges  and  technical  hurdles  faced  by
scientists working in the field of exosomes. It indeed shows how difficult it is to annotate
specific  molecular  markers,  i.e.  miRNAs  and  proteins,  to  exosomes  and  to  develop
analytical  tools  for  their  identification,  and  to  develop  large  scale  exosomes  isolation
methods generating highly pure exosomes preparations under sterile conditions for in vitro
and in vivo studies.
The characterization of exosomes is a crucial step when working in this field. It is of the
highest importance for further studies to make sure that the entities present in a sample
are indeed exosomes, especially if exosomes are meant to be used in  in vivo studies.
When going through the published works on exosomes, a striking observation was made
in the sense that there was no clear definition of what an exosome actually is, and which
markers  can be used to  show with  the  highest  confidence that  exosomes are  indeed
present in a sample, although efforts have been made to compile all these markers (110).
Surprisingly,  one  of  the  major  discrepancies  is  related  to  the  size  of  the  exosomes.
Although there is a trend indicating particles with a size around 80 nm, some papers also
include particles with a size between 30 and 100 nm (147,148), or even 200 nm (149,150)
in their definition of exosomes. It is therefore quite difficult to define exosomes hallmarks,
based only on particle size. The morphology of these particles is also often mentioned,
stating that exosomes are cup-shaped lipidic vesicles after visualization by Transmission
Electron Microscopy (TEM). However this cup-shape could just well be an artifact induced
by the various treatments required to visualize samples by TEM (151,152). Apart from size
and morphology, various reports also describe exosomes by determining their biochemical
and molecular biological content (49,132,153-158). Numerous studies were performed in
order to unravel the exosomal RNome and proteome in order to provide further insights
into the biological functions in which exosomes could be involved. Along these lines, many
studies showed that exosomes could be involved in the immune system, where they could
serve as intermediates between various actors of the immune system (159-162), or as
active entities able to  trigger signal  cascades inducing cell  death (163,164).  This is of
course to be taken in consideration when trying to develop drug delivery vehicles based on
exosomes, since that would mean that extreme care will have to be taken as to which sub-
class of exosomes can be used.
Although the role of exosomes in the immune system is gaining increasing interest, and
even if growing evidence is accumulating to demonstrate that exosomes can be involved
in  the  immune  system,  many  studies  also  describe  exosomes  as  simple  intercellular
communication means, and some only consider exosomes as a way for the cells to clear
out unwanted proteins, enzymatic activities, or nucleic acids (100,101,116). By comparing
reports defending these various hypotheses a trend slowly emerged with respect to the
most abundant or most representative miRNAs/proteins in exosomes (110,122).  These
studies  allowed  us  to  identify  miR-16-5p  as  one  of  the  most  abundant  miRNAs  in
exosomes, as well as CD63 and Alix as being major constituents of the exosomal protein
population. In this work I realized that exosomes characterization required the conjunction
of several of the markers mentioned previously, such as displaying the right particle size,
the right protein markers and showing the detergent-sensitive detection of the exosomes
content. Following this observation, it became clear to me that one has to be careful when
trying to demonstrate the implication of exosomes in a given biological process. One of the
key features in all exosomes-related works would be to perform an extensive and thorough
exosomes characterization study prior to being able to draw any conclusions as to the
effect of exosomes, such as showing exosomal hallmarks as well as several exosomal
markers.
The fact  that  none  of  the  methods  tested in  our  study allowed  us  to  detect  particles
displaying the three exosomes hallmarks which are their size, and several markers such
as Alix or miR-16-5p prompted us to not pursue any  in vitro nor  in vivo work. It would
indeed have been difficult to appreciate any biological activity if we would not have been
sure that our samples contained highly pure exosomes. Because of the complexity of the
input material (conditioned cell culture supernatant) it was crucial to make sure that no
other protein or vesicle could trigger a biological effect which could have led to a “false
positive”.  Although  some  results  were  clearly  encouraging,  such  as  seeing  a  direct
correlation between miR-16-5p and Alix signals in the same fractions of a linear sucrose
gradient, other factors such as exosomes amount and reproducibility issues for example
never  allowed  us  to  bring  the  project  to  the  next  step  which  was  the  in  vitro
characterization of exosomes-mediated siRNA delivery.
To sum up, I find it very interesting that although the first observation of exosomes was
made more than 25 years ago, it is only very recently that scientific consortiums emerged,
aiming at combining the efforts of the many scientists working on exosomes and affiliated
microvesicles. The combination of their knowledge and experience on exosomes could
potentially lead to the identification of novel and trustworthy exosomal markers, as well as
the  development  of  better  exosomes  isolation  processes.  Once  these  two  major
milestones are in place, I have no doubt that exosomes could eventually be used as anti-
cancer vaccines, as it was already reported from various authors (115,165-169). According
to these authors, the MHC complexes carried by the exosomes secreted by cancer cells
could elicit an immune response, and would therefore direct the immune response towards
cancer cells. 
Exosomes could however be useful in other fields of human health. They could indeed be
used as efficient disease diagnostic tools since they can be found in many biological fluids,
such as blood, urine, breast milk, or saliva. It could therefore be possible, by analyzing the
exosomes population secreted by a patient,  to detect proteins or nucleic acid moieties
indicating a certain type of cancer, inflammation, or disease (170-173). This has already
been observed for liver injuries, where in the case of an inflammatory liver disease for
example,  miR-122 levels  can be found  in  higher  amounts  in  exosomes,  compared  to
exosomes from healthy patients (174).
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VI. Conclusion and outlook
In  this  study,  we investigated the possibility  to  use exosomes as delivery vehicles for
siRNA, and we developed in parallel a PCR-based visualization method to study the  in
vivo biodistribution of oligonucleotides in mouse whole body sections.
We  successfully  developed  the  WBS-PCR  method  to  perform  oligonucleotides
biodistribution  studies,  including  endogenous  and  ectopic  mRNAs  and  non-coding
miRNAs, as well  as non-modified siRNAs. The detection of highly chemically modified
oligonucleotides, such as antagomirs for example, was possible as well with CL-qPCR, a
method  we  developed  which  was  also  shown  to  be  compatible  with  WBS-PCR.  We
therefore had a nice tool at our disposal to screen exosomes from various origins, and
various tissue-targeting peptides conjugated with exosomes for siRNA delivery. However,
our attempts in isolating exosomes were highly disappointing, since none of the methods
tested in this study resulted in an efficient isolation of pure exosomes, as could be seen by
the difficulty for our samples to meet the established criteria indicating the presence of
exosomes.  Although  two  of  the  methods  tested  are  clearly  mentioned  as  reference
methods  in  the  exosomes  field,  namely  differential  ultracentrifugation  and  ExoQuick
isolation, it remains unclear whether the samples we prepared by using these methods did
contain exosomes. Taken together, these observations indicate that despite an increasing
amount of publications on exosomes, work conducted on exosomes has to be extensively
controlled to make sure that the effect(s) attributed to exosomes are indeed due to these
vesicles. It would however be a huge step forward if we could use the exosomes as non-
invasive diagnostic tools, since they could provide, in a single saliva drop, access to the
circulating proteome and RNome of patients. 
VII. Material and methods
A. Whole-Body Scanning PCR
A.1. Oligonucleotides and RT-qPCR assays
Synthetic  RNA  sequences  and  DNA  PCR  primers  for  miRNA,  siRNA  and  antagomir
detection were ordered from Microsynth AG (Switzerland) (Supplementary table 1).
Supplementary Table 1: List of the reagents used for miRNA, siRNA and CL-qPCR assays
TaqMan  gene  expression  assays  were  ordered  from  Applied  Biosystems  (USA)
(Supplementary table 2).
Supplementary Table 2: List of the ABI Taqman assays
A.2. Design of miRNA and siRNA RT-qPCR primers
The RT-primer, which also serves as reverse primer during the PCR-reaction, contains a
generic sequence at the 5’-end and a Target Recognition Sequence (TRS) at the 3’-end.
The optimal  TRS sequence in  most  assays  consists  of  8  nucleotides but  can vary in
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length,  ranging  from  6  to  12  nucleotides,  depending  on  the  sequence  of  the  target
molecule. For example, if the 3’-end of the RT-primer ends with a palindromic motif (i.e –
ccgg, -aatt, -ggcc, -ttaa, -atat, -tata, -cgcg and -gcgc), the performance of the assay can be
considerably improved by either removing or extending the TRS sequence by a single
nucleotide  so  that  the  palindromic  sequence  is  disrupted.  The  generic  sequence  is
required to increase the Tm of the oligonucleotide and to modulate the G/C-content since
the same primer will function as reverse primer in the subsequent PCR-reaction.
The 5’-fluorophore labeled forward-primer contained a generic sequence at the 5’-end and
a gene-specific region spanning at least 12 nucleotides at the 3’-end. The optimal length of
the gene-specific region depends on the target sequence and the TRS length of the RT-
primer. Excessive overlap (more than 3 nucleotides) with the RT-primer and palindromic
sequences at the 3’-end should be avoided. The generic sequence of the forward-primer
should  be  complementary  to  the  quencher-labeled  anti-primer  sequence  (5’-
AAATCGAGGGAGGGAG-BHQ2-3’).
A.3. Synthetic miRNA standard curves preparation
Synthetic  miRNAs  were  serially  diluted  into  Poly(A)  (10  ng/μL  diluted  in  RNAse-free
water/GE Healthcare, #27-411-01) to generate a dilution series ranging from 10 ng/μL
down to 1 zg/μL. A sample containing only 10 ng/μL Poly(A) in RNase-free water was
included as No Template Control (NTC) and was used to determine the background level
of RT-qPCR primers.
A.4. siRNA duplex standard curve preparation
siRNA was serially diluted into 10 ng/μL total rat liver RNA to generate a dilution series
ranging from 10 ng/μL down to 1 zg/μL. A sample containing only 10 ng/μL Poly(A) in
RNase-free water was included as NTC and was used to determine the background level
of RT-qPCR primers.
A.5. AMO-miR-16 standard curves preparation
AMO-miR-16  was  serially  diluted  in  either  Poly(A)  (10  ng/μL  diluted  in  RNAse-free
water/GE  Healthcare,  #27-4110-01)  or  in  diluted  (1:750  in  RNAse-free  water)  tissue
lysates from a PBS treated mouse. The dilution series ranged from 8 ng/μL down to 0.8
zg/μL. A sample containing only 10 ng/μL Poly(A) in RNase-free water was included as
NTC and was used to determine the background level of RT-qPCR primers.
A.6. In vivo experiments
All  experimental  animal  procedures  were  approved  by  the  Animal  Care  and  Use
Committees of the Kanton Basel, Switzerland.
A.7. Whole tissue lysates preparation
Isolated organs were weighed, transferred into Lysing matrix A tubes (MP Biomedicals,
#16910050), frozen on dry ice and stored at -80°C until  processing. The tissues were
lysed  by  adding  10  volumes/weight  Clarity  OTX  buffer  (Phenomenex,  #AL0-8498)
supplemented with 20 mM TCEP (Sigma-Aldrich, #C4706-2G) followed by shaking for 60
seconds at 4m/s in a FastPrep-24 instrument (MP Biomedicals). Subsequently, tubes were
centrifuged at 4°C for 30 seconds at 12.000 rpm. Supernatant was transferred to a fresh
tube and stored at  -80°C. The concentrated lysates  were  diluted 1:750 in  RNase-free
water prior to RT-qPCR analysis. Diluted lysates should be stored at -80°C and repeated
freeze-thawing cycles should be avoided.
A.8. Implantation of HCT116 tumor in mice
The human colorectal carcinoma cell  line, HCT-116 (Catalog #CCL-247), was obtained
from ATCC (Rockville, Maryland, USA). The cells were maintained and cultured according
to established techniques as recommended by the supplier. Briefly, HCT-116 cells were
cultivated in McCoy's  5A medium (Amimed/Bioconcept,  #1-18F01-I) supplemented with
10% v/v FCS (Amimed/Bioconcept, #2-01F26-I), 2 mM L-Glutamine (Amimed/Bioconcept,
#5-10K00-H) and 2.2 g/L sodium pyruvate (Amimed/Bioconcept, #5-60F00-H). Cells were
split 1:8 or 1:10 every 3rd or 4th day depending on confluence. Female Hsd:Athymic nude
mice  (Harlan  Laboratories,  Nederland)  at  age  of  6-7  weeks  were  group  housed  in
individually  ventilated  cages  with  access  to  food  and  water  ad  libitum.  Tumors  were
established  by  subcutaneous  injection  of  5×106 cells  in  100  µl  of  HBSS  (Invitrogen,
#14175-046)  per  mouse  into  the  left  flank  of  the  animals  under  Isoflurane  (Provet,
Lyssach, Switzerland) anesthesia. Tumor volume and body weight were monitored twice
weekly. The tumor volume was 429 mm3 at the time of sacrifice (38 days after inoculation).
A.9. Mrp4 siRNA QWBA
Male  albino  CD-1  mouse  (Charles  River  France,  29-32  g)  received  intravenous
administration of unformulated [3H]-MRP4 siRNA in 0.9% sodium chloride at a dose of 5
mg/kg,  under  anesthesia  (by  inhalation  of  an  oxygen/isoflurane  mixture)  as  a  bolus
injection into the vena saphena. The dose volume was 2 mL/kg, and the total amount of
radioactivity administered was 21 MBq/kg. The mouse was sacrificed by deep isoflurane
inhalation at 10 minutes post i.v. dosing. Whole body sections were prepared as described
previously and exposed for two weeks to Fuji BAS III imaging plates (Fuji Photo Film Co.,
Ltd., J-Tokyo) in a lead-shielded box at room temperature, and scanned in a Fuji BAS
5000 phosphor imager (Fuji Photo Film) at a 50 µm scanning step.
A.10. AMO-miR-16 injection
Mice were treated intravenously with 80 mg/kg AMO-miR-16 (dissolved in PBS) via tail
vein injection. Blood plasma was collected pre- and 5, 10, 30, 60, 240, 360 and 1440
minutes post dosing. Mice were sacrificed at 1440 minutes post-dosing and prepared for
whole body sectioning or tissue sampling as described previously.
A.11. Whole Body sectioning
Right  after  sacrifice,  animals  were  submerged  in  -70°C n-hexane  (VWR International,
#BREN81631-156) / dry ice mixture for about 30 min. The carcasses were stored at -80°C
until embedding and all subsequent procedures were performed at temperatures of about
-20°C to minimize diffusion of compound. The frozen carcasses were embedded in a mold
on  a  microtome  stage  by  adding  an  ice-cold  aqueous  solution  of  2%
carboxymethylcellulose (low viscosity,  Sigma-Aldrich Chemie GmbH, #C5678-1KG) and
freezing it by placement in an n-hexane/dry ice bath for about 40 minutes. The frozen
block  was  removed  from  the  mold  and  stored  at  -20°C  until  sectioning.  Whole-body
sections were performed in the sagittal plane (from cranial to caudal) using CM3600XP
cryomacrotome (Leica Microsystems),  and the sections collected on an adhesive  tape
(Scotch Magic Tape 810, 118 mm x 66 m, Voegtli Bürotechnik AG, #1939899). Several
sections of 40 µm thickness were taken at varying depths throughout the body. Sections
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were mounted on a wooden frame after collection and dehydrated for 72 h at -23°C in the
cryomacrotome chamber. The sections were stored at -20°C until further handling.
A.12. WBS-PCR
Firstly, a picture of the section was taken using a ChemiDoc XRS+ System from Bio-Rad.
Subsequently,  a matrix of  363 wells  was outlined on a 1,536-well  Polypropylene plate
(Greiner Bio-One, #789270) with a permanent pen (Staedtler) and each well was filled with
15 μL Clarity OTX buffer (Phenomenex,  #AL0-8498) supplemented with 20 mM TCEP
(Sigma-Aldrich, #C4706-2G). The whole body section was placed within the matrix on the
plate  (tissue  facing  the  well)  and  firmly  sealed  with  a  Microseal  `B´  film  (Bio-Rad,
#MSB1001) with the help of a rubber brayer (Speedball). Another picture of the section
was  taken  at  this  point  and  was  used  in  the  data  analysis  process.  The  plate  was
subsequently inversed several times, and centrifuged for 3 minutes at 1,450 g in a Sigma
4-15C centrifuge (Qiagen) containing a Nr 09100 rotor (Qiagen). Lysates were transferred
to a 384-well Hard-Shell PCR Plate (Bio-Rad, #HSP3901) and stored at -80°C. Samples
were diluted 1:75 in RNase-free water prior to RT-qPCR analysis. Diluted lysates should
be stored at -80°C and repeated freeze-thawing cycles should be avoided.
A.13. Quantification of rRNA and mRNA
The detection of 18S rRNA and various mRNAs was performed in a one-step reaction. 8
μL RT-qPCR mix  containing:  5.35  μL  DEPC-water,  0.15  μL 100  mM dNTPs (Applied
Biosystems, #362271), 1 μL 10x PCR Buffer I (Applied Biosystems, #4379876), 1 μL 25
mM MgCl2 (Roche, #12032953001), 0.1 μL Rox Reference Dye (Invitrogen, #12223-012),
0.2 μL Assay On Demand (Applied Biosystems),  0.1 μL Multiscribe (50 U/μL) (Applied
Biosystems,  #4319983),  0.1  μL  Hot  Start  Taq  Polymerase  (5  U/μL)  (Roche,
#12032953001) was  added to  a 384-well  Hard-Shell  PCR Plate (Bio-Rad,  #HSP3901)
followed  by  the  addition  of  2  μL  sample.  After  sealing  (Microseal  `B´  film,  Bio-Rad,
#MSB1001), the plate was mixed and centrifuged for 3 min at 1.450 g. The PCR reaction
was  performed  in  a  7900HT  Fast  Real-Time  PCR System  (Applied  Biosystems)  and
consisted of 1 cycle: 30 minutes/50°C, 1 cycle: 10 minutes/ 95°C followed by 40 cycles: 3
seconds/95°C; 30 seconds/60°C. The data was acquired and analyzed using the software
provided by Applied Biosystems. In accordance with Applied Biosystems guidelines, Ct
values bigger as 35 were considered as noise.
A.14. Quantification of 18S genomic DNA
The detection of 18S genomic DNA was performed in a one-step reaction. 8 μL qPCR mix
containing: 5.45 μL DEPC-water, 0.15 μL 100 mM dNTPs (Applied Biosystems, #362271),
1 μL 10x PCR Buffer  I  (Applied  Biosystems,  #4379876),  1  μL 25 mM MgCl2 (Roche,
#12032953001), 0.1 μL Rox Reference Dye (Invitrogen, #12223-012), 0.2 μL Assay On
Demand  (Applied  Biosystems),  0.1  μL  Hot  Start  Taq  Polymerase  (5  U/μL)  (Roche,
#12032953001) was added to each well  of a 384-well  Hard-Shell PCR Plate (Bio-Rad,
#HSP3901) followed by the addition of 2 μL sample. After sealing (Microseal `B´ film, Bio-
Rad, #MSB1001), the plate was mixed and centrifuged for 3 min at 1.450 g. The PCR
reaction was performed in a 7900HT Fast Real-Time PCR System (Applied Biosystems)
and consisted of 1 cycle: 10 minutes/ 95°C followed by 40 cycles: 3 seconds/95°C; 30
seconds/60°C.  The  data  was  acquired  and  analyzed  using  the  software  provided  by
Applied Biosystems. In accordance with Applied Biosystems guidelines, Ct values bigger
as 35 were considered as noise.
A.15. Quantification of miRNA and siRNA
The detection of miRNAs and siRNAs was performed in a two-step reaction. In the first
step, 8 μL RT-mix containing: 5.65 μL DEPC-water,  0.15 μL 100 mM dNTPs (Applied
Biosystems, #362271), 1 μL 10x PCR Buffer I (Applied Biosystems, #4379876), 1 μL 25
mM MgCl2 (Roche, #12032953001), 0.1 μL 1 μM RT-primer, 0.1 μL Multiscribe (50 U/μL)
(Applied Biosystems, #4319983) was added to each well of a 384-well Hard-Shell PCR
Plate (Bio-Rad, #HSP3901) followed by the addition of 2 μL sample. The plate was sealed
(Microseal `B´ film, Bio-Rad, #MSB1001), mixed, centrifuged and incubated for 10 minutes
at 25°C followed by 5 minutes at 95°C in a 7900HT Fast Real-Time PCR System (Applied
Biosystems).  Before  unsealing,  the  plate  was  centrifuged for  3  min  at  1.450 g  and 5
μL/well PCR mix was added. Subsequently, the plate was sealed (Microseal `B´ film, Bio-
Rad, #MSB1001), mixed and centrifuged for 3 min at 1.450 g. The PCR mix contained:
3.325 μL DEPC-water, 0.15 μL 100 mM dNTPs (Applied Biosystems, #362271), 0.5 μL
10x  PCR  Buffer  I  (Applied  Biosystems,  #4379876),  0.5  μL  25  mM  MgCl2 (Roche,
#12032953001), 0.15 μL 10 μM forward primer, 0.15 μL 10 μM reverse primer, 0.075 μL
50 μM Anti-primer, 0.15 μL Hot Start Taq Polymerase (5 U/μL) (Roche, #12032953001).
The PCR reaction was performed in a 7900HT Fast  Real-Time PCR System (Applied
Biosystems)  and  consisted  of  1  cycle:  10  minutes/95°C  followed  by  50  cycles:  3
seconds/95°C; 30 seconds/55°C. The ramping speed should not exceed 3°C/s. The data
was acquired and analyzed using the software provided by Applied Biosystems. Signals
that did not fall within the linear range of the standard curve were considered as noise.
A.16. Quantification of AMO-miR-16
The quantification of AMO-miR-16 was performed in a two-step reaction. In the first step, 8
μL Chemical Ligation-mix containing: 5.8 μL DEPC-water, 1 μL 10x PCR Buffer (Roche
#14882500), 1 μL Poly(A) (1 μg/μL diluted in RNAse-free water/GE Healthcare, #27-4110-
01), 0.1 μL 10 μM PS-Ligator (5’-TTAAACCATAGCAGCACG-PS-3’), 0.1 μL 10 μM BPS-
Ligator  (5’-BPS-TAAATATTGGCGAACCAGT-3’)  was  added to  each well  of  a 384-well
Hard-Shell  PCR Plate (Bio-Rad,  #HSP3901) followed by the addition of  2 μL sample.
Subsequently,  the  plate  was  sealed  (Microseal  `B´  film,  Bio-Rad,  #MSB1001),  mixed,
centrifuged for 3 minutes at 1.450 g and incubated for 30 minutes at 33°C in a 7900HT
Fast  Real-Time  PCR  System  (Applied  Biosystems).  Before  unsealing,  the  plate  was
centrifuged.
Upon completion of the chemical  ligation reaction,  8 μL PCR-mix containing 6.375 μL
DEPC-water,  0.15 μL 100 mM dNTPs (Applied Biosystems,  #362271),  1 μL 10x PCR
Buffer (Roche #14882500), 0.15 μL 10 μM forward primer, 0.15 μL 10 μM reverse primer,
0.075  μL  50  μM  Anti-primer,  0.1  μL  Hot  Start  Taq  Polymerase  (5  U/μL)  (Roche,
#12032953001) was added to each well of a new 384-well  Hard-Shell PCR Plate (Bio-
Rad,  #HSP3901)  followed  by  the  addition  of  2  μL  of  the  Chemical  Ligation-mix.
Subsequently, the plate was sealed (Microseal `B´ film, Bio-Rad, #MSB1001), mixed and
centrifuged for 3 min at 1.450 g. The PCR reaction was performed in a 7900HT Fast Real-
Time  PCR  System  (Applied  Biosystems)  and  consisted  of  1  cycle:  10  minutes/95°C
followed by 50 cycles: 3 seconds/95°C; 30 seconds/55°C; 10 seconds/72°C. The ramping
speed should not exceed 3°C/s. The data was acquired and analyzed using the software
provided by Applied Biosystems. Signals that did not fall  within the linear range of the
standard curve were considered as noise.
A.17. Statistical analysis
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The statistical  relevance of the results obtained for the quantification of miR16-5p and
AMO-miR-16 was tested by Mann-Whitney Rank Sum Test. A t-test was performed on the
values obtained for miR-191-5p quantification.
A.18. Imaging of the WBS-PCR data
RT-qPCR data of the whole body sections was deconvoluted in Excel and converted into a
TissueView™ compatible  image  file  using  an  Excel  to  Analyze  Conversion  macro
(http://maldi.ms). Subsequently, the RT-qPCR image data was loaded into TissueView™
(AB Sciex, Toronto) and overlaid with an image of the whole body section.
A.19. Building block synthesis for chemical ligators
All  reactions were  carried  out  under  an  atmosphere  of  argon.  Solvents  for  extraction:
technical  grade  from  Brenntag  Schweizerhalle  AG.  Solvents  for  reactions:  anhydrous
quality  from  Sigma-Aldrich.  Base-protected  deoxynucleosides  were  obtained  from
ChemGenes  (N6-benzoyl-2’-deoxyadenosine  #PM-1101,  N4-benzoyl-2’-deoxycytidine
#PM-1102,  N2-isobutyryl-2’-deoxyguanosine  #PM-1103,  thymidine  #DN-1004).  All  other
reagents  were  purchased  from  Sigma-Aldrich,  highest  quality  available,  unless  stated
otherwise. Flash-chromatography was performed using silica gel 60 with a particle size of
40-63 m (Merck). Thin layer chromatography was performed on Merck silica gel 60 F254
plates  which  were  visualized  by  UV  irradiation  (254  nm).  NMR:  Bruker  DRX-400,
deuterated  solvent  as  indicated,   in  ppm,  calibration  to  residual  solvent  peaks,  13C
multiplicities derived from DEPT spectra, 31P calibration to external H3PO4 ( = 0 ppm).
A.20. Synthesis of base protected 5’-O-biphenylsulfonyl-2’-
deoxynucleosides
Supplementary Figure 1: Chemical synthesis of 5’-O-biphenylsulfonyl-2’-deoxynucleosides (a) and of 5’-O-
biphenylsulfonyl-2’-deoxynucleosides phosphoramidites (b)
5 mmol of the starting base protected deoxynucleoside 1 – 4 (Supplementary Figure 1a)
is dried by dissolving it twice in 20 mL anhydrous pyridine and evaporating the solvent.
The nucleoside is redissolved in 20 mL anhydrous pyridine and cooled to -20°C (4°C for 3)
before adding 1.52 g (6.00 mmol)  biphenyl-4-sulfonyl  chloride.  The reaction mixture is
stirred for 2 days at -20°C (4°C for 3). After completion, the reaction is quenched by the
addition of 5 mL water  and stirring is continued for 15 min at room temperature.  The
reaction mixture is then taken up in 100 mL dichloromethane and washed with saturated
aqueous sodium bicarbonate solution (2 x 50 mL) and brine (50 mL). The aqueous layers
are washed twice with 50 mL dichloromethane each. The combined organic phases are
dried  over  anhydrous  sodium  sulfate,  filtered,  and  evaporated.  Residual  pyridine  is
removed  by repeated  co-evaporation  with  toluene  (3  x  10  mL).  The  crude product  is
purified by flash chromatography yielding the 5’-O-biphenylsulfonyl-2’-deoxynucleoside 5 –
8 as off-white foam. Analytical data see Supplementary Table 3.
Supplementary Table 3: Analytical NMR data obtained for each of the compounds synthesized in Supplementary
Figure 1
A.21. Synthesis of N-protected 5’-O-biphenylsulfonyl-2’-
deoxynucleoside phosphoramidites
To a solution of 5.00 mmol of the N-protected 5’-O-biphenylsulfonyl-2’-deoxynucleoside 5
–  8 in  25  mL  anhydrous  dichloromethane  under  argon  is  added  1.28  g  (7.50  mmol)
diisopropylammonium-tetrazolide (prepared from tetrazole and diisopropylamine or from
Chem-Impex,  #00951).  Then  2.22  mL  (2.11  g,  7.00  mmol)  2-cyanoethyl  N,N,N',N'-
tetraisopropylphosphordiamidite (Aldrich 97%, #305995) is added and the solution stirred
at  room  temperature  overnight.  The  reaction  mixture  is  taken  up  in  100  mL
dichloromethane and extracted with aqueous bicarbonate solution (2 x 50 mL) and brine
(50 mL). The aqueous phases are reextracted with 50 mL dichloromethane. The combined
organic phases are dried over sodium sulfate, filtered, and evaporated. The remaining oil
is chromatographed on silica to give a mixture of diastereomeric 5’-O-biphenylsulfonyl-2’-
deoxynucleoside phosphoramidites 9 – 12 (Supplementary figure 1b) as colorless brittle
foam. Analytical data see Supplementary Table 3.
A.22. Synthesis of oligodeoxynucleotides with 3’-terminal 
phosphorothioate
DNA  oligonucleotides  were prepared  on  a  MerMade  192  well  DNA/RNA  Synthesizer
(BioAutomation)  on  a  scale  of  200  nmol.  TheraPure™  deoxyribonucleoside
phosphoramidites were dissolved in anhydrous acetonitrile at a concentration of 0.1 M.
The activator, 5ethylthiotetrazole (ChemGenes, #RN-6397), was dissolved in acetonitrile
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as a 0.5 M solution. Capping solution A consisted of acetic anhydride (Fluka, #45830) and
2,6-lutidine (Aldrich, #336106) in anhydrous THF (Aldrich, #401757) at a ratio of 1:1:8
(v/v/v)  and  capping  solution  B  of  16%  (v/v)  1-methylimidazole  (Aldrich,  #336092)  in
anhydrous  THF.  The  oxidation  solution  was  prepared  by  dissolving  iodine  (Aldrich,
#207772) in a 1:1:8 (v/v/v) mixture of 2,6-lutidine, water and THF for a final concentration
of  0.1  M.  Deblocking  solution  was  4% (v/v)  dichloroacetic  acid  (Aldrich,  #D54702)  in
dichloromethane (Aldrich, #270997). Sulfurizing reagent consisted of a 0.05 M solution of
3-((dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-3-thione (Sulfurizing Reagent II,
Glen  Research,  #40-4037-20)  in  pyridine/acetonitrile  3:2  (v/v).  The  synthesis  cycle
consisted of the following steps: 1) detritylation with deblocking solution (2 x 90 μL, 10 sec
each), wash with acetonitrile (2 x 100 μL); 2) coupling reaction with a 6:1 (v/v) mixture of
activator and phosphoramidite solution (2 x 35 μL, 3 min each), wash with acetonitrile (2 x
100 μL); 3) capping with a 1:1 (v/v) mixture of capping solutions A and B (100 μL, 20 sec)
wash with acetonitrile (2 x 100 μL); 4) oxidation with iodine solution (100 μL, 60 sec) wash
with acetonitrile (2 x 100 μL). Reagents are applied to the top of the columns and allowed
to  react  for  the  time  indicated.  For  their  removal  a  gentle  vacuum is  applied  as  per
manufacturer’s instructions. Oligodeoxynucleotides are synthesized without removing the
5’-terminal dimethoxytrityl  group. For the preparation of DNA oligonucleotides with a 3’-
terminal  thiophosphate  a  prepacked  200  nmol  synthesis  column  (BioAutomation)  was
emptied  and charged  with  5  mg of  3’-phosphate  CPG (Glen Research,  #20-2900-01)
(175). The following cycle is applied in the first coupling: 1) detritylation with deblocking
solution (2 x 90 μL, 10 sec each), 2) coupling reaction with a 6:1 (v/v) mixture of activator
and phosphoramidite solution (2 x 35 μL, 3 min each), wash with acetonitrile (2 x 100 μL);
3) sulfurization with sulfurizing reagent II (100 μL, 60 sec) wash with acetonitrile (2 x 100
μL); 4) capping with a 1:1 (v/v) mixture of capping solutions A and B (100 μL, 20 sec) wash
with acetonitrile (2 x 100 μL). The oligodeoxynucleotides were detached from solid support
and deprotected by treating with concentrated ammonia (Merck, #1.05426.1000) at 55°C
overnight. The ammonia solution was filtered off and the resin washed with 500 μL water.
The  filtrate  was  lyophilized  and  the  residue  redissolved  in  1  mL  aqueous  0.1  M
triethylammonium acetate buffer pH 7.0. The crude oligodeoxynucleotide was purified on a
Oasis  HLB  96-well  plate  (30  μm  particle  size,  Waters,  #WAT058951)  applying  the
following protocol: 1) each well used is equilibrated by washing with 500 μL acetonitrile
and  1mL  aqueous  0.1  M  triethylammonium  acetate  buffer  pH  7.0;  2)  the
oligodeoxynucleotide solution above is applied to a single well; 3) the resin is washed with
1 mL 15% acetonitrile/water (v/v); 4) the DMT group is removed by applying 1 mL 3%
aqueous dichloroacetic acid;  5) wash with  2 x 1 mL aqueous 0.1 M triethylammonium
acetate buffer pH 7.0; 6) column is sucked dry by applying a gentle vacuum from the
bottom;  7)  apply  530  μL  acetonitrile/water  1:1  (v/v)  and  collect  oligonucleotide.  The
oligodeoxynucleotide solutions were evaporated on a plate lyophilizer (GeneVac, HT-4x)
and the residue redissolved in water for a 80 μM stock solution. Purity and identity of all
oligonucleotides were verified by LC-MS analysis (Thermo Scientific Accela 600 pumps,
Accela  PDA  detector,  and  LCQ  Fleet  MS,  equipped  with  a  PAL  System  HTS  PAL
autosampler).
A.23. Synthesis of 5’-O-biphenylsulfonyl-derivatized 
oligodeoxynucleotides
Oligodeoxynucleotides  containing  a  5’-O-biphenylsulfonyl  group  were  synthesized  at  a
scale  of  200  nmol  as  described  above,  except  that  Ultramild  CE  phosphoramidites
(http://www.glenresearch.com/Technical/TB_UltraMild_Deprotection.pdf)  for  regular
deoxynucleosides were used and for the final  coupling step phosphoramidites  9 –  12.
Capping  was  performed  with  phenoxyacetic  anhydride  (Aldrich,  order  no.  77750)
substituting acetic anhydride. For deprotection, the CPG was treated with concentrated
ammonia for 4 hrs at room temperature. Purification was achieved as above on Oasis HLB
reverse phase cartridges, except that steps 4) and 5) were omitted.
A.24. Oligonucleotide synthesis
Phosphoramidites  for  200  –  800  μmol  syntheses  of  fully  2’-O-methyoxyethyl-modified
oligoribonucleotides  were  custom  synthesized  (176).  Control  pore  glass  (CPG)  solid
supports  with  preloaded  2’-O-methyoxyethyl  ribonucleoside  monomers  were  custom
synthesized starting from commercially available amine modified CPG (Prime Synthesis,
LCAA/CNA CPG, #CPG601N12). Ultramild CE phosphoramidites for 200 nmol syntheses
of  5’-O-biphenylsulfonyl-modified  oligodeoxynucleotides  were  purchased  from  Glen
Research (Pac-dA-CE Phosphoramidite  #10-1601-10,  Ac-dC-CE Phosphoramidite  #10-
1015-10,  iPr-Pac-dG-CE  Phosphoramidite  #10-1621-10,).  TheraPure™  DNA
phosphoramidites  were  purchased  from Thermo Scientific  (Bz-dA-CE Phosphoramidite
#27-2030-00, Bz-dC-CE Phosphoramidite #27-2032-00, iBu-dG-CE Phosphoramidite #27-
2034-00, dT-CE Phosphoramidite #27-2036-00). Support for DNA oligonucleotides with a
3’-thiophosphate  was  obtained from Glen Research (3’-Phosphate CPG #20-2900-10).
Anhydrous acetonitrile for oligonucleotide synthesis was purchased either from Biosolve
(#012058, <10 ppm water) or from Sigma Aldrich (#L0114000-01, <30 ppm water). Sterile
water for buffers and oligonucleotide solutions was obtained from a Milli-Q Advantage A10
station (Millipore).
A.25. AMO-miR-16 synthesis
The base-protected 2’-O-methoxyethyl ribonucleoside phosphoramidites were dissolved in
anhydrous  acetonitrile  at  a  concentration  of  0.15  M.  AMO-miR-16  synthesis  was
performed on an Äkta Oligopilot plus OP100 (GE Healthcare) with the help of a 12 mL
column  reactor  (GE  Healthcare,  #18-1101-16)  using  solid-phase  synthesis  cyclic
procedure consisting of 5 steps, based on the manufacturer’s template method. First, the
4,4'-dimethoxytrityl  (DMT) protecting group was removed by adding deblocking reagent
(3% DCA in toluene, Merck, #BI0832). Coupling was then achieved by adding the n+1
phophoramidite  solution  to  the  column  along  with  an  equal  volume  of  0.5  M  5-
ethylthiotetrazole  (ChemGenes,  #RN-6397)  in  acetonitrile.  Coupling  was  followed  by
capping by adding Cap A (Biosolve, #036124) and Cap B, obtained by mixing equivalent
amounts  of  Cap  B1  (Biosolve,  #037424)  and  Cap  B2  (Biosolve,  #037425).  The
oligonucleotide  was  subsequently  oxidized  by  adding  iodine  (Biosolve,  #150724).  The
column  was  washed  between  each  step  with  anhydrous  acetonitrile.  The  synthesis
procedure ended with a final detritylation step in order to remove the last DMT-group and
allow easier purification. After synthesis the column was placed under vacuum in order to
remove all remaining acetonitrile, and the support was transferred into a glass vial. The
oligonucleotide was cleaved from the support and deprotected by incubating the support
with  60  mL  conc.  ammonia  solution  32% (Merck,  #105426)  overnight  at  50°C  under
agitation.  The  solution  was  subsequently  filtered  on  a  Steritop  filter  unit  (Millipore,
#SCGPT05RE) and the filter was rinsed with water. The oligonucleotide was purified on a
Fineline pilot 35 column (GE Healthcare, #18-1102-02) filled with TSK Gel SuperQ-5PW
ion exchange resin (Tosoh, #18546) using an ÄKTAexplorer (GE Healthcare). Fractions of
appropriate purity were pooled and then desalted by tangential flow filtration (TFF) on a
Minim II TFF system (Pall Corporation) using a 1K Omega Centramate T-Series filtration
unit (Pall Corporation, #OS001T12). The oligonucleotide was filtered again on a Steriflip-
GP filtration unit (Millipore, #SCGP00525) and the quality of the oligonucleotide verified by
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HPLC and UPLC-MS. Prior to injection into animals, endotoxin levels were assessed using
the Endosafe-PTS system (Charles River) and PTS cartridges (Charles River, #PTS2005).
B. Exosomes isolation and characterization
B.1. Cell culture
HeLa (ATCC® CCL-2™), MS1 (ATCC® CRL-2279™) and 3T3 (ATCC® CRL-1658™) were
from ATCC. Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (GIBCO,
#32430)  supplemented  with  10%  v/v  fetal  calf  serum  (FCS)  (Invitrogen,  #10270106)
without  antibiotics.  For exosomes isolation, cells were grown until  confluence in T-150
flasks (TPP, #90151), at which point the medium was replaced with 30 mL fresh DMEM
supplemented with 10% v/v FCS. The conditioned medium was collected 48 hours after
medium exchange and subjected to exosomes isolation.
B.2. TCEP Lysis Buffer
The TCEP lysis buffer was prepared by diluting 100 µL 0.5 M HCl (Fluka, #84435), 500 µL
100% Triton-X-100 (Roche, #10789704001) and 75 mg TCEP (Sigma Aldrich, #4706-10G)
in 50 mL DEPC-water. The lysis buffer was stored at 4°C until further handling.
B.3. Exosomes isolation with the ExoQuick exosome precipitation 
solution
The entire procedure was performed in a tissue culture hood.  Conditioned cell  culture
medium was collected in sterile Falcon tubes and centrifuged at 3,000 g for 15 minutes at
4°C to remove dead cells and cell debris. The supernatant was transferred to a new sterile
Falcon tube and was supplemented with ExoQuick exosome precipitation solution (SBI,
#EXOQ20A-1)  in  a  1:1  ratio  and  incubated  overnight  at  4°C.  The  solution  was
subsequently centrifuged at 1,500 g at 4°C for 30 minutes. The supernatant was discarded
and the remaining drops were collected at the bottom of the tube by centrifugation at 1,500
g at  4°C for  5  minutes.  The remaining  solution  was  discarded,  without  disturbing  the
pelleted material. The precipitated material was resuspended in 1/10 of the original volume
in  PBS  (GIBCO,  #20012019)  supplemented  with  protease  inhibitors  (Roche,
#11873580001), and stored at 4°C until further handling.
B.4. Differential ultracentrifugation for exosomes isolation
The entire procedure was performed in a tissue culture hood. The cell culture supernatant
was collected from three T-150-flasks in 50 mL sterile Falcon tubes and centrifuged at
3,000 g for 10 minutes at 4°C. The supernatant was collected in fresh 50 mL Falcon tubes
and centrifuged again for 10 minutes at 3,000 g at 4°C, to remove dead cells and cell
debris.  The  supernatant  was  collected  and  transferred  to  3  36  mL  tubes  (Beckman
Coulter, #344058) from the SW40 swinging bucket rotor, and centrifuged at 100,000 g for
1 hour at 4°C. The supernatants were discarded and each pellet was dissolved in 1.5 mL
PBS (GIBCO, #20012019) supplemented with protease inhibitors (Roche, #11873580001).
The dissolved pellets were collected in a 5 mL tube (Beckman Coulter, #328874) from the
SW60Ti  swinging  bucket  rotor  and  centrifuged  at  100,000  g  for  1  hour  at  4°C.  The
supernatant  was  discarded  and  the  pellet  was  dissolved  in  150  µL  PBS  (GIBCO,
#20012019)  supplemented  with  protease  inhibitors  (Roche,  #11873580001).  A  100%
sucrose solution was prepared by dissolving 100 g of sucrose (Sigma, #S1888) in PBS
(GIBCO, #20012019) supplemented with protease inhibitors (Roche, #11873580001). This
100% sucrose solution was dissolved in PBS with protease inhibitors to prepare solutions
containing 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 and 70% sucrose. The linear
sucrose gradient was prepared by overlaying 1mL of each of the sucrose solutions in a 16
mL tube (Beckman Coulter, #331372) from the SW40 swinging bucket rotor.  The 70%
sucrose solution was added at the bottom of the tube, using a sterile 2mL Plastipak™ Luer
Slip syringe (BD, #300185) and a sterile 21G 0.8 x 40 mm needle (BD, #304432). The
65% sucrose solution was added on top of the 70% sucrose fraction by applying the end of
the needle on the wall of the tube, and letting the solution flow gently along the wall, so
that both solutions do not mix. This procedure was repeated for all the sucrose-containing
solutions.  The exosomes solutions  was  adjusted to  10% sucrose and overlaid  on  the
gradient using the same procedure. The gradient was subsequently centrifuged at 100,000
g for 16 hours at 4°C. After centrifugation, the 200 µL fraction on top of the gradient was
discarded. 1 mL fractions were pipetted off the gradient and transferred to 5 mL tubes from
the SW60Ti swinging bucket rotor. The gradient fractions were supplemented with 3 mL
PBS with protease inhibitors and centrifuged at 100,000 g for 1 hour at 4°C to pellet the
exosomes from each sucrose gradient fraction. The supernatant was discarded and the
pellets were dissolved in 50 µL PBS with protease inhibitors. The dissolved pellets were
stored at 4°C until further handling.
B.5. Exosomes isolation by ultrafiltration
Conditioned cell  culture supernatant  was subjected to  ultrafiltration using the 100 kDa
(Pall,  #OD100C36)  or  300 kDa (Pall,  #OD300C37)  molecular  weight  cut-off  Macrosep
devices. Prior to sample treatment, the devices were pre-rinsed by adding 15 mL DEPC
water to the filtration unit and centrifuging the device at 4,500 g for 30 minutes at 4°C. The
water collected in the recipient unit was discarded. The devices were sanitized by adding
15  mL 70% ethanol  in  the  filtration  unit,  followed  by centrifugation  at  4,500  g  for  30
minutes at 4°C. The ethanol collected in the recipient unit was discarded and the devices
were  washed  by  adding  15  mL  DEPC  water  to  the  filtration  unit.  The  devices  were
centrifuged at 4,500 g for 30 minutes at 4°C and the water collected in the recipient unit
was discarded. 15 mL conditioned medium were added to the filtration unit and centrifuged
at 4,500 g for  30 minutes at 4°C. The flow-through,  located in  the recipient  unit,  was
collected  in  sterile  Falcon  tubes  and  stored  at  4°C.  The  remaining  unprocessed
conditioned medium was added to the filtration unit,  and centrifuged at 4,500 g for 30
minutes at 4°C. The second flow-through was collected in a sterile Falcon tube and stored
at 4°C. The retentate, composed of the particles retained by the membrane in the filtration
unit,  was  washed  three  successive  times  by  adding  15  mL  PBS  supplemented  with
protease inhibitors on the retentate, and subjecting the device to centrifugation at 4,500 g
for 30 minutes at 4°C. The retentate was subsequently dissolved in 500 µL PBS with
protease inhibitors and stored at 4°C until further handling.
B.6. Exosomes isolation by Tangential Flow Filtration
Prior  to  processing  of  the  conditioned  cell  culture  supernatant,  the  Minimate™-TFF-
System (Pall, #OAPMP220) mounted with a 100 kDa molecular weight cut-off membrane
(GE Healthcare,  #UFP-100-C-MM01A) was flushed with  100 mL DEPC water  under  a
maximum filtrate speed of 1 mL/min and keeping the pressure below 1 bar. The system
was  then  washed  with  200  mL 100  mM NaOH (Fluka,  #72082)  in  DEPC water.  The
system was washed with  DEPC water  until  the pH of the filtrate  was down to 7.  The
system was purged and 500 mL conditioned cell culture supernatant were added in the
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sample vessel.  The TFF system was kept to a circulating speed of 1 mL/min and the
pressure was kept below 1 bar. 100 mL sterile PBS supplemented with Protease inhibitors
was added to the system as soon as the volume in  the sample vessel  was just  high
enough to allow the solution to flow in the tubing. This step was repeated 5 times in total.
The solution remaining in the sample vessel  and tubing (retentate) was collected in a
sterile 15 mL Falcon tube and stored at 4°C as soon as the retentate volume was too low
to circulate properly in the TFF system. The system was subsequently washed with 500
mL 100 mM NaOH in DEPC water.
B.7. Samples preparation for Triton-dependent RT-qPCR
The exosome samples  were  transferred  to  a 96-well  plate  and supplemented with  an
equivalent volume of either TCEP Lysis Buffer or PBS. The plate was then place on a
shaker  for  5  minutes  and  centrifuged  for  15  seconds  at  1,450  g.  The  samples  were
subsequently diluted 1 in 10 in DEPC water and stored at -20°C until further handling.
B.8. Polybrene/CSC precipitation
After collection, the conditioned medium was centrifuged at 3,000 g for 30 minutes at 4°C
to remove dead cells and cell  debris.  The supernatant was transferred to fresh sterile
Falcon tubes and was supplemented with TrisHCl buffer pH 7.5 to a final concentration of
100 mM. Polybrene (Sigma, #107689) diluted in PBS was added to the cell culture to a
final concentration of 100 µg/mL and the solution was incubated for 30 minutes at 4°C,
under agitation. Chondroitin sulfate C (Sigma, #C4384) was added to the solution to a
concentration ranging between 0 and 5 mg/mL. The solution was incubated for 30 minutes
at 4°C under agitation and centrifuged at 3,000 g for 30 minutes at 4°C. The supernatant
was discarded and the pellet was dissolved in 10 mL PBS supplemented with Protease
inhibitors.  The  solution  was  centrifuged  at  3,000  g  for  30  minutes  at  4°C  and  the
supernatant was discarded. The pellet was resuspended in 200 µL PBS supplemented
with protease inhibitors. The pellets were stored at 4°C until further handling.
B.9. Particle size determination by Dynamic Light Scattering
The particle size distribution of the exosomes preparation was determined on a Zetasizer
Nano ZS (Malvern). 20 µL exosomes solution were diluted in 380 µL PBS and transferred
in a single-use cuvette.  The parameters used for the measurements are the following:
Materil RI: 1.45; Dispersant name: PBS; Dispersant RI: 1.335; Viscosity: 1.0200.
B.10. Western Blotting
13  µL  samples  were  supplemented  with  5  µL  4x  LDS  Loading  Buffer  (Invitrogen,
#NP0007) and 2 µL Reducing agent (Invitrogen, #NP0004) and incubated at 70°C for 10
minutes under agitation (1,000 rpm). The samples were loaded on a NuPAGE® Novex® 4-
12% Bis-Tris gel (Invitrogen, #NP0322PK2). 5 µL of Protein ladder (Bio-Rad, #161-0376)
and Western blot protein ladder (Bio-Rad, #161-0381) were loaded on the gel to monitor
protein migration during electrophoresis and after western blotting. Protein migration was
performed using MOPS SDS running buffer (Invitrogen, #NP0001) for 50 minutes at 200
V.  The semi-dry  transfer  was  performed by  overlaying  2  layers  of  whatman paper,  a
nitrocellulose membrane, the gel and 2 layers of whatman paper avoiding the presence of
bubbles  between  the  various  layers  and  adding  enough  transfer  buffer  (Invitrogen,
#NP0006) to keep all layers wet. The transfer was performed at 160 mA for 2 hours. The
membrane was blocked in 5% milk (Bio-Rad, #170-6404) in TBS-Tween for 1 hour at 4°C.
The primary antibody (Supplementary Table 4) was incubated on the membrane in 5%
milk in TBS-Tween for 1 hour at room temperature or overnight at 4°C, under agitation.
The membrane was washed 3 times with TBS-Tween for 5 minutes, and incubated with
the secondary antibody (Supplementary Table 4) in 5% milk in TBS-Tween for 1 hour at
room temperature.
Targe
t
Primary antibody Secondaryantibody
Reference Dilution Reference
Dilutio
n
CD63 sc-15363 1:1000 sc-2077 1:5000
Alix sc-53540 1:200 sc-2096 1:5000
Supplementary Table 4: Primary and secondary antibodies used for the detection of CD63 and Alix proteins
The membrane was washed 3 times 5 minutes with TBS-Tween. The blot was revealed by
incubating it  with  ECL+ (GE Healthcare, #RPN2132) and a picture was taken using a
BioRad XRS ChemiDoc station, and analyzed with the software Quantity One.
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